



MIHAELA ANDREESCU

(Nume anterioare: Tevet, Closca-Gheorghiu, Gheorghiu)

Data nașterii: 19/03/1975 | Cetățenie: română |
, 002134, Bucuresti, România

EXPERIENȚA PROFESIONALĂ

02/2024 - ÎN CURS

Conferentiar Universitar – Universitatea Titu Maiorescu Bucuresti; Facultatea de Medicina

- Hematologie - anul VI Medicina Generala,
- Hematology - anul VI Medicine in English
- Terapie Regenerativa cu Celule Stem - optional anul V Medicina Generala si an V Medicine in English,
- Ingrijiri Specializate in Hematologie - anul IV AMG

2025 - ÎN CURS

MEMBRU AL GRUPULUI TEHNIC DE LUCRU MULTIDISCIPLINAR PENTRU IMPLEMENTAREA ȘI MONITORIZAREA MĂSURILOR PRIVIND PREVENȚIA ȘI CONTROLUL CANCERULUI – Ministerul Sanatatii România

2023 - ÎN CURS

MEMBRU IN COMISIA NATIONALA DE CLASIFICARE A CAZURILOR DE REACTII ADVERSE POSTVACCINALE INDEZIRABILE – Ministerul Sanatatii România

2023 - ÎN CURS

MEMBRU IN COMISIA DE ONCOLOGIE – Ministerul Sanatatii România

2022 - ÎN CURS

MEMBRU SI SECRETAR IN COMISIA DE HEMATOLOGIE – Colegiul Medicilor România

02/2021 - 2024

Sef de Lucrari – Universitatea Titu Maiorescu Bucuresti; Facultatea de Medicina

- Hematologie - anul VI Medicina Generala,
- Hematology - anul VI Medicine in English
- Terapie Regenerativa cu Celule Stem - optional anul V Medicina Generala si an V Medicine in English,
- Ingrijiri Specializate in Hematologie - anul IV AMG
- Bioetica - anul II MG

2015 - ÎN CURS

MEMBRU IN COMISIA DE HEMATOLOGIE – Ministerul Sanatatii România

2014 - ÎN CURS

MEMBRU FONDATOR SI SECRETAR GENERAL AL SOCIETATII ROMANE DE TRANSPLANT MEDULAR - România

09/2014 - 03/2016 si 02/2022 - in curs

MEDIC SEF DE SECTIE HEMATOLOGIE, respectiv SEF SECTIE HEMATOLOGIE CLINICA I – Spital Clinic Colentina, Bucuresti, România

- Coordonarea activitatii sectiei de Hematologie
- Coordonator rezidenti, activitate didactica studenti in cadrul UTM - Facultatea de Medicina

2013 - ÎN CURS

MEDIC PRIMAR SECTIA CLINICA HEMATOLOGIE I – Spital Clinic Colentina, Bucuresti, România

- participare in trialuri clinice,
- co-participant in proiecte cercetare,
- efectuare foi observatie pacienti, examen clinic pacienti, completare condici medicatie, completare evolutie pacienti internati, stabilire indicatii terapeutice pacienti,

12/2012 - 06/2013

MEDIC SPECIALIST SECTIA HEMATOLOGIE – Spital Clinic Colentina, Bucuresti, România

- participare in trialuri clinice,
- co-participant in proiecte cercetare,
- efectuare foi observatie pacienti, examen clinic pacienti, completare condici medicatie, completare evolutie pacienti internati, stabilire indicatii terapeutice pacienti,
- efectuare garzi

2006 - 2012

MEDIC SPECIALIST - ASISTENT CERCETARE, ULTERIOR CERCETATOR STIINTIFIC – Spital Clinic Coltea, Bucuresti, România

- participant la proiecte cercetare,
- trialuri clinice,
- medic specialist pe sectia hematologie - garzi, stabilire indicatii terapeutice pacienti

2001 - 2006

MEDIC REZIDENT - ASISTENT CERCETARE – Spital Clinic Coltea, Bucuresti, România

- participare in trialuri clinice,
- co-participant in proiecte cercetare,
- efectuare foi observatie pacienti, examen clinic pacienti, completare condici medicatie, completare evolutie pacienti internati

1999 - 2000

MEDIC STAGIAR – Spital Judetean Sf Apostol Andrei, Galati

- efectuare foi observatie,
- examen clinic pacienti, completare condici medicatie,
- completare evolutie pacienti internati in sectiile medicina interna si chirurgie unde s-au efectuat stagiile
- garzi ca medic generalist voluntar in UPU Spital Judetean Galati

1998 - 1999

REPREZENTANT MEDICAL – Knoll BASF Pharma

- reprezentant medical pe Constanta, Slobozia si Calarasi

EDUCAȚIE ȘI FORMARE PROFESIONALĂ

02/03/2020 - 29/07/2020 - Bucuresti, România

ATESTAT MANAGEMENTUL SERVICIILOR DE SANATATE – Scoala Nationala de Sanatate Publica, Management si Perfectionare in Domeniul Sanitar Bucuresti

01/04/2019 - 30/09/2019

ULTRASONOGRAFIE GENERALA – UMF "Carol Davila" Bucuresti

2007 - 2014 - Bucuresti, România

DOCTOR IN MEDICINA – UMF Carol Davila

- Tema: Mutatia Jak2 V617F in mieloproliferarile cronice - Importanta in patogenie, corelatie cu date demografice, elemente clinice, paraclinice si complicatii

2013 - ÎN CURS - România

MEDIC PRIMAR HEMATOLOGIE – Ministerul Sanatatii

2008 - ÎN CURS - România

CERCETATOR STIINTIFIC – Academia Romana de Stiinte Medicale

2009 - România

CERTIFICAT DE ABSOLVIRE CURS MANAGER DE PROIECT – Ministerul Educatiei si Cercetarii

- Managementul proiectelor de cercetare

2006 - 2013 - România

MEDIC SPECIALIST HEMATOLOGIE – Ministerul Sanatatii

2005 - 2008

ASISTENT DE CERCETARE – Academia Romana de Stiinte Medicale

2001 - 2006

MEDIC REZIDENT HEMATOLOGIE CLINICA – Ministerul Sanatatii

COMPETENȚE LINGVISTICE

Limbă(i) maternă(e): ROMÂNĂ

	COMPREHENSIVNE			VORBIT	SCRIS
	Comprehensiune orală	Citit	Exprimare scrisă	Conversație	
ENGLEZĂ	C1	C1	C1	C1	C1
FRANCEZĂ	A2	B1	A1	A1	A1

Niveluri: A1 și A2 Utilizator de bază B1 și B2 Utilizator independent C1 și C2 Utilizator experimentat

● **COMPETENȚE DIGITALE**

Microsoft Office Word Excel Power Point Outlook

Utilizare buna a programelor de comunicare (Teams Mail)

UtilizareMail(Yahoo Mail Gmail)

O foarte buna stapanire a utilizarii internetului

Social Media Management (Social Ads)

● **COMPETENȚE ORGANIZATORICE**

Organisational skills

- Abilitati de structurare,
- Capacitate de sinteza,
- Abilitati decizionale

● **COMPETENȚE DE COMUNICARE ȘI INTERPERSONALE**

Communication and interpersonal skills

- Experienta de lucru in cadrul echipelor multidisciplinare din cadrul unitatilor spitalicesti
- Experienta in management de proiect/implementare de proiecte -Experienta lucrului in echipa
- Abilitate de comunicare cu pacientul, empatie, creativitate, dinamism, eficienta, spirit de echipa, abilitate de a comunica cu oameni din toate mediile sociale/culturale

● **JOB-RELATED SKILLS**

Job-related skills

- Efectuez punctii medulare, biopsii osteo-medulare, paracenteze,

● CARTI PUBLICATE

- ***Terapie regenerativa cu celule stem. Note de curs. Editura Hamangiu, 2023, autor: Dr. Mihaela Andreescu; Alina Daniela Tanase; ISBN 978-606-27-2330-9***
- ***Bioetica si Deontologie medicala. Note de curs. Avatarul unui ideal, Editura Universitatii „Titu Maiorescu”, 2023, autor: Dr. Mihaela Andreescu; Tony Tudor Andrei; ISBN 978-606-767-108-7***
- ***Avortul recurent, Editura Amaltea, 2019, autor: Dr. Mihaela Andreescu; ISBN 978-973-162-201-9***
- ***Hematologia in practica medicala, Editura Universitatii "Carol Davila" Bucuresti,2005; Autori: Prof. dr. Anca Roxana Lupu, co-autori : Oana Ciocan, Anca Ciobanu, Mihaela Closca-Gheorghiu, Laura Bleotu, Cristina Ciufu, Diana Cisleanu***
- ***Regenerative Therapy with Stem Cells (English edition). Editura Hamangiu, 2024, autori: Dr. Mihaela Andreescu, Alina Daniela Tanase, Cosmin Moldovan; ISBN 978-606-27-2479-5***
- ***COVID-19 Mucormycosis in Medical Science: Trends and Innovations Vol. 2 (Capitol). Volum international colectiv, 2024, autor capitol: Andreescu M et al.***

Am participat in 13 proiecte de cercetare NATIONALE si INTERNATIONALE

- 2022 - asistent implementare in cadrul proiectului de cercetare „Evaluarea multimodala prin biomarkeri noi si tehnici de imagistica avansata a cardiomiopatiei cu transtiretina - un mod mai bun de a trata” AMYLO-HEART-PRESERVED, UMF Carol Davila Bucuresti;
- 2016 - PNIII-P2-2.1-PED-2016-1315 - "The role of microparticles in the pathogenetic mechanisms of vascular complications in patients with chronic myeloproliferative neoplasms" - Colentina Clinical Hospital coordinator
- 2016, January, Hematology Necker - ROMANIA ATLL PROJECT in colaboration with Hôpital universitaire Necker, Paris, France, Institut Imagine, Paris, France, Emergency University Hospital Bucharest si Roumanian Association against Leukemia – Colentina Clinical Hospital coordinator
- PN-II-PT-PCCA-2013-4-0930 - " Design and testing of a new family of specific drug HIV Integrase inhibitors which do not interfere with V(D)J recombination" - Colentina Clinical Hospital coordinator
- 2016 European HIVERA Horizon 2020 - HIVERA-INinRAGI - " Screening and developing of a novel family of natural and synthetic HIV Integrase inhibitors "- Consortium of 5 teams- Coordinator - Colentina Hospital Bucharest and Partners: Hungary (University of Szeged, Dr. Hohmann's group), Latvia (Center For Advanced Chemical Synthesis Riga Dr. Abele's group), Hungary Budapest(Center For Epidemiology Dr. Mezey's group), Romania (Institute of Biochemistry, Dr. A.J. Petrescu's, – Colentina Clinical Hospital coordinator
- CEEEX 96/2006- Integration of molecular biology techniques and cytogenetic examinations in diagnosis of tumor splenomegaly - etiopathogenic factors, prognostic and therapeutic implications, Sept. 2006 - 2008;
- CEEEX 3442/111/2/2006- Complex, cellular, molecular and genetic approach to new pathogenic mechanisms in malignant myeloproliferation, project in partnership with Université Catholique de Louvain, Brussels, Christian de Duve Institute of Cellular Pathology, Ludwig Institute for Cancer Research, Belgium, Sept .2006 – 2008;
- CEEEX 75/2006 - The value of the molecular typification of the hla profiles to optimize donor selection for allograft haematopoietic stem cells and for the initiation of the Romanian national donor registry; Sept 2006 – 2008;
- PN II-41-087 - Molecular monitoring of hybrid BCR-ABL oncogene in chronic myeloid leukemia (CML) through quantitative Real-Time PCR: Foundation of national registry for CML patients, 2007-2010;
- PN II -41-093 - Expression of molecules associated with cellular signal and gene rearrangement - clonal molecular markers identified in the development of B cell lymphoma. Foundation of national registry for follicular lymphoma, 2007-2010;
- CEEEX 95/2006 - Family screening, genetic analysis and monitoring of people at risk of Mamar cancer, Sept .2006 – 2008;
- Approach to improvement of haemophilia care in Romania. Project won by international competition in August 2006; 2007-2008, member of the working group coordinated by Prof. Dr. Margit Serban
- Phase III Randomized, Multicenter International Study for aggressive lymphomas - NHL13 and follicular lymphoma - MAXIMA, Sub Investigator

● PUBLICATII

Articole indexate Google Scholar:

1. „MECOM, HBS1L-MYB, THRB-ARB, JAK2 and TERT polymorphism defining the genetic predisposition to myeloproliferative neoplasms: study on 939 patient” Authors: Adrian P. Trifa, Cllaudiia Banescu, Anca S. Bojan, Cristian M. Voinea, Stefana Popa, Simona Visan, Alina D. Ciubean, Florin Tripon, Delia Dima, Viola M. Popov, Stefan C. Vesa, Mihaela Andreescu, Tunde Torok-Vistai, Romeo G. Mihaila, Nicoleta Berbec, Ioan Macarie, Andrei Colita, Maria Iordache, Alina C. Catana, Marius F. Farcas, Ciprian Tomuleasa, Kinga Vasile, Cristina Truica; published in American Journal of Hematology 2018 Jan;93(1):100-106. doi: 10.1002/ajh.24946. Epub 2017 Nov 10; **impact factor 5.303 (2018); Quartile: Q1**
2. „TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.” - Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrengea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Patrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA. British Journal of Haematol. 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. Epub 2016 Apr 7; **impact factor 5.401 (2016) Quartile: Q1**
3. „Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders.” - Tevet M, Ionescu R, Dragan C, Lupu AR. Maedica (Bucharest). 2015 Mar;10(1):27- 32
4. „2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications” - Jan Jacques MICHIELS; Mihaela TEVET, Adrian Trifa, Emilia Niculescu-Mizil, Anca Lupu, Ana Maria Vladareanu, Horia Bumbea, Anca Ilea, Camelia Dobrea, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Meilin Murat, Cornel Dragan, Felicia Mihai, Sabina Zurac, Silvana Angelescu, Anamaria Iova, Alina Popa, Rodica Gogulescu, Viola Popov - MAEDICA - a Journal of Clinical Medicine 2016; 11(5): 5-25 **Quartile: Q1**
5. Andreescu, M., Frîncu F, Plotogea M, Mehedințu C. Recurrent Abortion and the Involvement of Killer-Cell Immunoglobulin-like Receptor (KIR) Genes, Activated T Cells, NK Abnormalities, and Cytokine Profiles. J Clin Med. 2023 Feb 8;12(4):1355. doi: 10.3390/jcm12041355. PMID: 36835892; PMCID: PMC9968158. **IF 4.965 (2023) Quartile: Q3**
6. Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma—Romanian Experience. AD Tanase, A Colita, OG Craciun, L Lipan, Z Varady, L Stefan, A Ranete, M. Andreescu. Journal of Clinical Medicine 9 (8), 2417; **impact factor 0,68 (2020) Quartile: Q4**
7. „CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.” - Trifa AP, Popp RA, Cucuianu A, Bănescu C, Tevet M, Martin B, Murat M, Vesa SC, Dima D, Căndea M, Militaru MS, Pop IV. British Journal of Haematol. 2015 Jan; 168(1): 151-3. doi: 10.1111/bjh.13076. Epub 2014 Aug 8; **impact factor 4.711 (2015) Quartile: Q1**
8. „Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms” Trifa AP1,2, Bănescu C3, Dima D4, Bojan AS4,5, Tevet M6, Moldovan VG3, Vesa C7, Murat M6, Pop IV1, Skrypnik C8, Popp RA1. - Hematology Journal. 2016 Oct; 21(9):520-5. doi: 10.1080/10245332.2016.1163889. Epub 2016 Mar 30; **impact factor 2 (2016) Quartile: Q3**
9. „Multiple intestinal Lymphoma” - Mastalier B, Deaconescu V, Elaiha W, Drăghici C, Popp C, Zurac S, Balea M, Tevet M, Botezatu C. Rom J Intern Med. 2015 Jan-Mar;53(1):73-8; **impact factor 0.683 (2015) Quartile: Q4**
10. Andreescu, M. (2023). The Impact Of the Use Of Immunosuppressive Treatment After An Embryo Transfer In Increasing The Rate Of Live Birth. Frontiers Med., (10). <https://doi.org/10.3389/fmed.2023.116787>. **IF 5.058 (2023) Quartile: Q1**
11. Andreescu, M. (2023). The link between immune thrombocytopenia and the cytokine profile: a bridge to new therapeutical targets. Frontiers in Hematology, 2. <https://doi.org/10.3389/frhem.2023.1191178>. **IF 5.058 (2023) Quartile: Q1**
12. „Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia” Authors: Adrian P. Trifa, Claudia Banescu, Cristian M. Voinea, Stefana Popa, Tunde Torok-Vistai, Anca S. Bojan, Delia Dima, Mihnea Zdrengea, Bogdan Fetica, Simona Visan, Ciprian Tomuleasa, Andrada Parvu, Laura Urian, Bogdan Pop, Viola M. Popov, Mihaela Andreescu, Radu A. Popp.; published in Blood Cells, Molecules and Diseases 7392018) 45-46; **impact factor 1.836 (2018) Quartile: Q3**
13. Andreescu M. Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies. Cureus. 2024 Jan 4;16(1):e51662. doi: 10.7759/cureus.51662. PMID: 38179322; PMCID: PMC10766007; **impact factor 1.0 (2024)**
14. Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence, Horia Bumbea, MD PhD, Ambroise Marçais, MD PhD, Daniel Coriu, MD PhD, Alina Daniela Tanase, MD PhD, Andrei Colita, MD PhD, Alexandru Bardas, MD, Anca Roxana Lupu, MD PhD, Ana-Maria Vladareanu, MD PhD, Minodora Cezarina Onisai, MD PhD, Viola Maria Popov, MD PhD MSc, Iuliana Iordan, MD, Magda Diana Cisleanu, MD PhD, Daniela Stefania Vasile, MD PhD, Cristina Maria Ciufu, MD PhD, Zsofia Varady, MD PhD, Oana Gabriela Craciun, MD, Daniela Georgeta Georgescu, MD PhD, Mihaela Andreescu, MD PhD, Cristina Mambet, MD, Carmen C. Diaconu, PhD, Laura Necula, PhD, Monica Bunaciu, Adriana Necula, Stefan N Constantinescu, MD PhD, Olivier Hermine, MD PhD, Blood (2019) 134 (Supplement_1): 5288; **impact factor 17.543 (2019)**
15. Andreescu M. Molecular Insights Into the Role of Gut Microbiota in Antibiotic Therapy Selection and Resistance

- Mitigation. *Cureus*. 2023 Dec 11;15(12):e50318. doi: 10.7759/cureus.50318. PMID: 38089944; PMCID: PMC10714069; **impact factor 1.0 (2023)**
16. "Immunotherapy with Rituximab in Follicular Lymphomas" - Carmen SAGUNA, MD,a Ileana Delia MUT, MD, PhD, Anca Roxana LUPU, MD, PhD,a Mihaela TEVET, MD, SR,a Horia BUMBEA, MD, PhD,b and Cornel DRAGANA, *Maedica* 2011, 2011April; 6(2): 100-108
 17. Andreescu, M. Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies. *Life* 2023, 13, 1272. <https://doi.org/10.3390/life13061272>. **IF 3.257 (2023) Quartile: Q2**
 18. Mihaela Andreescu, Alina Tanase, Bogdan Andreescu, Cosmin Moldovan; A review of Immunological Evaluation of Patients with Recurrent Spontaneous Abortion (RSA); 2025/1/17; *International Journal of Molecular Sciences*, vol. 26, nr. 2, pg. 785, editor MDPI; **Quartile: Q2**
 19. Andreescu M, Moldovan C, Lespezeanu DA, Mocanu AI, Schipor MA, Mocanu H. COVID-19-Associated Rhinocerebral Mucormycosis, an Incidental Finding or a Matter of Concern - Mixed-Method Systematic Review. *Infect Drug Resist*. 2024 Jan 31;17:387-402. doi: 10.2147/IDR.S445458. PMID: 38312523; PMCID: PMC10838509; **impact factor 2.9 (2024)**
 20. Andreescu M. Correlation Between Maternal-Fetus Interface and Placenta-Mediated Complications. *Cureus*. 2024 Jun 16;16(6):e62457. doi: 10.7759/cureus.62457. PMID: 38882223; PMCID: PMC11180486; **impact factor 1.0 (2024)**
 21. Andreescu M, Andreescu B. Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy. *Cureus*. 2024 Jan 22;16(1):e52737. doi: 10.7759/cureus.52737. PMID: 38384647; PMCID: PMC10880808; **impact factor 1.0 (2024)**
 22. Andreescu M. Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies. *Cureus*. 2024 Jan 10;16(1):e52050. doi: 10.7759/cureus.52050. PMID: 38344573; PMCID: PMC10857843; **impact factor 1.0 (2024)**
 23. Plotogea, M.; Zgura, A.; Mehedințu, C.; Scurtu, F.; Petca, A.; Varlas, V.N.; Bors, R.G.; Edu, A.; Ionescu, O.-M.; Andreescu, M.; et al. Women's Sexual Dysfunctions Following Stem Cell Transplant and the Impact on Couple Relationship. *Life* 2024, 14, 35. <https://doi.org/10.3390/life14010035> **Quartile: Q2**
 24. Andreescu, M.; Berbec, N.; Tanase, A.D. Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine- Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia. *J. Clin. Med.* 2023, 12, 2731. <https://doi.org/10.3390/jcm12072731>, **IF 4,965 (2023)**
 25. Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia. M Omer, AM Vladareanu, VM Popov, M Andreescu, L Iliescu, H Bumbea, *Revista Romana de Medicina de Laborator* 29 (4), 377-385; **impact factor 1.027 (2021)**
 26. "Pathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm" - Viola Maria Popov, Mihaela Andreescu, Ana Maria Vladareanu, Ion Dumitru, Felicia Mihai, Horia Bumbea - *Hematology and Transfusion International Journal*, 6(2) 50-53, 2018, ISSN: 2469-2778
 27. Andreescu M, Andreescu B. A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery. *Cureus*. 2024 Mar 12;16(3):e56008. doi: 10.7759/cureus.56008. PMID: 38606222; PMCID: PMC11007487; **impact factor 1.0 (2024)**
 28. Andreescu M (November 30, 2023) Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy. *Cureus* 15(11): e49696. doi:10.7759/cureus.49696; **impact factor 1.0 (2023)**
 29. Oprea-Lebedenco M, Berbec N, Stanca O, Turbatu A, Marin S, Dobrea C, Mihaela Andreescu et al. Classic Hodgkin Lymphoma- mixed cellularity - case report and review of literature. *Ro J Med Pract*. 2023;18(1):28-30. doi:10.37897/RJMP.2023.1.5; **impact factor 0.08 (2023)**
 30. CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL? V Popov, H Bumbea, M Andreescu, G Ofiteru, F Mihai, M Popescu, M Andreescu - *Clinical Lymphoma Myeloma and Leukemia* 22, S260; **impact factor 2.822 (2022)**
 31. AML-168: the assessment of COVID-19 evolution in patients with oncological diseases admitted in an intensive care unit of one Romanian center. VM Popov, L Iliescu, C Pirvu, A Grigorie, O Constantin, A Rus, M. Andreescu. *Clinical Lymphoma Myeloma and Leukemia* 21, S285-S286; **impact factor 3.231 (2021)**
 32. The Importance of CD36 Expression in Evaluation of Thrombotic Risk in Patients with Myeloproliferative Neoplasms- Viola Popov, MD PhD MSc, Meilin Omer, MD, Adrian Trifa, MD PhD, ION Dumitru, MD, Oana Patrinoiu, MD PhD, Mihaela Andreescu, MD PhD, Horia Bumbea, MD PhD -*Blood* (2018) 132 (Supplement 1): 4989., <https://doi.org/10.1182/blood-2018-99-115349>; **impact factor 15.132 (2018)**
 33. "Laparoscopic Splenectomy – Optimal Solution in Autoimmune Trombocytopenic Purpura" - B. Mastalier, W. Elaiah, Violeta Deaconescu, Irina Gal-Penciu, M. Leoveanu, Ioana Simion, C. Draghici, Mihaela Tevet, Sabina Zurac, C. Botezatu, *International Multidisciplinary Research Journal, European Academic Research*; **impact factor 0.5014 (2015)**
 34. „Secondary Acute Lymphoblastic Leukemia after Hodgkin's Lymphoma or a Coincidental Association of Two Hematological Malignancies?" - Tevet M, Dragan C, Saguna C, Barbu D, Lupu AR. *Maedica (Buchar)*. 2013 Sep;8(4):370-6.
 35. Managing HIV-Associated Hodgkin Lymphoma During the COVID-19 Pandemic: Case Report and Literature Review - Author(s): Monica-Daniela Padurariu-Covit, Mihaela Andreescu, Elena Niculet, Alina Plesea-Condratovici, Manuela Arbune; *Viruses* 2025, 17, 404. <https://www.mdpi.com/1999-4915/17/3/404> ; **impact factor 3.8 (2025)**
 36. Evaluation of Prognostic Factors Involved in the Evotion of Secondary Acute Leukemia Patients- Author(s): Meilin Omer, Viola Maria Popov, Horia Bumbea, Mihaela Andreescu, Maria Bacanu, Mihaela Popescu, Geanina Ofiteru, Lidia Felicia Mihai, Oana Patrinoiu, Ion Dumitru, Dan Sebastian Soare, Aurora Arghir, Ana Maria Vladareanu; 2024/11/5; *Blood*; vol. 144, pg. 6141; **impact factor 21.0 (2024)**
 37. Secondary acute promyelocytic leukemia in a patients with antecedent chemotherapy for breast carcinoma and multiple myeloma- case report- Author(s): Meilin Omer, Mihaela Popescu, Viola Popov, Oana Patrinoiu, Felicia Mihai, Geanina Ofiteru, Mihaela Andreescu, Cristina Mambet, Ana-Maria Vladareanu; 2024/10/1; *Oncolog-Hematolog*; vol. 69, nr. 4
 38. Particularities of Evolution in Acute Leukemia Patients With a History of Neoplasms- Retrospective Analysis- Author(s):

- Meilin Omer, Viola Maria Popov, Mihaela Andreescu, Horia Bumbea, Oana Patrinoiu, Mihaela Popescu, Felicia Mihai, Geanina Ofiteru, Aurora Arghir, Dan Soare, Ion Dumitru, Ana Maria Vladareanu; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal; vol. 24, pg.S173, editor Elsevier; **impact factor 2.7 (2024)**
39. A primary pulmonary determination- a rare form of marginal B-cell lymphoma: a case report- Authors: VM Popov, M Voicu, D Constantinescu, F Mihai, AD Sion, H Bumbea, MD Davidescu, C Dobra, M Andreescu; 2024/9/1, Clinical Lymphoma Myeloma and Leukemia Journal, vol. 24, S221, editor Elsevier; **impact factor 2.7 (2024)**
 40. MPN-123 Complex Clonal Evolution in a Patient with Advanced Myelofibrosis Exhibiting Bone Marrow Hypercellularity and Chromosomal Anomalies- Authors: Maria Bacanu, Viola Maria Popov, Dumitru Jordan, Camelia Dobra, Mirela Voicu, Dan Constantinescu, Mihaela Andreescu, Meilin Omer; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal, vol. 24; pg. S416; editor Elsevier; **impact factor 2.7 (2024)**
 41. AML-546 Particularities of Evolution in Acute Leukemia Patients with a History of Neoplasms- Retrospective Analysis- Authors: Meilin Omer, Viola Maria Popov, Mihaela Andreescu, Horia Bumbea, Oana Patrinoiu, Mihaela Popescu, Felicia Mihai, Geanina Ofiteru, Aurora Arghir, Dan Soare, Ion Dumitru, Ana Maria Vladareanu; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal; vol. 24, pg. S319-S320; editor Elsevier; **impact factor 2.7 (2024)**
 42. IBCL-094 A Primary Pulmonary Determination- A Rare Form of Marginal B-Cell Lymphoma: A Case Report- Authors: Viola Maria Popov, Mirela Voicu, Dan Constantinescu, Felicia Mihai, Alexandru Dragos Sion, Horia Bumbea, Mihnea Dan Davidescu, Camelia Dobra, Mihaela Andreescu; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal; vol. 24, pg. S493; editor Elsevier; **impact factor 2.7 (2024)**
 43. MM-121 Extramedullary Multiple Myeloma- Report of a Case Manifested as a Retroperitoneal Mass and Cholestatic Syndrome- Authors: Viola Maria Popov, Dan Constantinescu, Gabriel Constantinescu, Bogdan Diaconescu, Valentin Enache, Camelia Dobra, Mirela Voicu, Mihaela Andreescu; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal; vol. 24,pg. S537; editor Elsevier; **impact factor 2.7 (2024)**
 44. Andreescu M. Correlation Between Maternal-Fetus Interface and Placenta-Mediated Complications. Cureus. 2024 Jun 16;16(6):e62457. doi: 10.7759/cureus.62457. PMID: 38882223; PMCID: PMC11180486; **impact factor 1.0 (2024)**
 45. Andreescu M. Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies. Cureus. 2024 Jan 4;16(1):e51662. doi: 10.7759/cureus.51662. PMID: 38179322; PMCID: PMC10766007; **Res**
 46. A comparative approach to classifications in the diagnosis of acute myeloblastic leukemia with reference to cytogenetic, myelodysplastic elements and mutations of the TP53 gene - WHO, ICC, ELN 2022- Authors: Meilin Omer, Mihaela Andreescu, Viola Maria Popov, Ana-Maria Vladareanu; 2024/1/1; Oncolog-Hematolog journal; nr. 66; **impact factor 3.4 (2023)**
 47. PO07 Is Covid-19 a Trigger Factor for Thrombotic Complications in Late Pregnancy?- Authors: V. Popov, B. Mastalier, L. Iliescu, M. Andreescu; 2023/10/1; Research and Practice in Thrombosis and Haemostasis journal; vol. 7, editor Elsevier; **impact factor 3.4 (2023)**
 48. CML-084 COVID-19 - Trigger for Chronic Myeloid Leukemia Evolution?- Authors: Viola Popov, Mihaela Andreescu; 2023/9/1; Clinical Lymphoma Myeloma and Leukemia journal; vol. 23, pg. S333; editor Elsevier; **impact factor 2.7 (2023)**
 49. Andreescu, M. (2023). The Impact Of the Use Of Immunosuppressive Treatment After An Embryo Transfer In Increasing The Rate Of Live Birth. *Frontiers Med.*, (10). <https://doi.org/10.3389/fmed.2023.116787>. **IF 5.058 (2023) Quartile: Q1**
 50. Mihaela Andreescu. Recurrent Pregnancy Loss in Thrombophilia and Role of Anticoagulation Therapy: A Systematic Review. *Perceptions Reprod Med.* 5(4). PRM. 000618. 2023. DOI: 10.31031/PRM.2023.05.000618. **Impact Factor: 3.153 (2023)**
 51. Andreescu M, Ilie N, Andrei TT, Lacatusu A, Olteanu S, et al (2023) Post-Polycythemia Vera Myelofibrosis (PPVMF)- A Case Report of a Patient Transplanted after an Adverse Reaction to Covid Vaccination. *Ann Case Report.* 8: 1182. DOI:10.29011/2574-7754.101182, **Impact Factor = 4.48 (2023)**
 52. Mihaela Andreescu1,2*, Nicoleta Ilie2, Andreea Lacatusu2, Tudor Tony Andrei2, Laura-Gabriela Tirlea2, Andreea Brasoveanu2, Ionescu Rozeta2, Viola Popov2. Long Covid Case Report: Post SARS-CoV-2 Infection Evolution in Follicular Non-Hodgkin's Malignant Lymphoma, under Monoclonal Anti-CD20 Antibodies Treatment. *Merit Research Journal of Medicine and Medical Sciences* (ISSN: 2354-323X) Vol. 11(2), February, 2023. Available online <http://www.meritresearchjournals.org/mms/index.htm>, ISSN 2354-323X, DOI: 10.5281/zenodo.7653420, ISI **Impact Factor = 1.425 (2023)**
 53. Andreescu M, Zurac S, Lacatusu A, Tudor AT, Ilie N, Tirlea LG, et al. Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin's lymphoma. *Rev Romana Med Lab.* 2023;31(1):59-64. DOI:10.2478/rrlm-2023-0007, **IF 1.027 (2023)**
 54. Poster: CLL-033 Is Covid-19 infection a Trigger for Progression of CLL?- Authors: Viola Popov, Horia Bumbea, Mihaela Andreescu, Geanina Ofiteru, Felicia Mihai, Mihaela Popescu, Oana Patrinoiu, Daniela Georgescu, Claudia Despan, Meilin Omer; 2022/9/21; Clinical Lymphoma, Myeloma & Leukemia journal; vol. 22, pg. S140; **impact factor 2.822 (2022)**
 55. P1602: THE ASSESSMENT OF LYMPHOPENIA AS RISK FACTOR FOR UNFAVORABLE EVOLUTION OF PATIENTS WITH SEVERE FORM OF COVID 19. V Popov, L Iliescu, A Grigorie, C Pirvu, O Constantin, A Badea, M Andreescu. *HemaSphere* 6 (Suppl); **impact factor 8.300 (2022)**
 56. P1601: THE ASSESSMENT OF PREDICTIVE ROLE OF PROTEIN C AND S FOR CRITICAL FORM OF COVID-19. V Popov, M Andreescu, O Patrinoiu, M Popescu, M Omer, F Mihai, *HemaSphere* 6 (Suppl); **impact factor 8.300 (2022)**
 57. The importance of the long Covid-19 in the evolution of patients with neoplasms. V Popov, M Andreescu, C Pirvu, A Grigorie, O Constantin, A Calen, *Journal of Clinical Oncology* 40 (16_suppl), e18647-e18647; **impact factor 50.717 (2022) Quartile: Q1**
 58. Lymphopenia: A predictive marker of disease severity in COVID-19 infection. GD GEORGESCU, M BALEA, V POPOV, M ANDREESCU, M MUNTEANU, *Romanian Journal of medical Practice* 16 (4); **impact factor 0.118 (2021)**
 59. Survival analyses of COVID-19 in patients with hemato-oncological diseases admitted in Intensive Care Unit. V Popov, L Iliescu, M Omer, MDB Niculae, C Pirvu, O Constantin, M Andreescu - *American Journal of Hematology*,

- S32-S32; **impact factor 10.047 (2021) Quartile: Q1**
60. Poster: AML-168: the assessment of COVID-19 evolution in patients with oncological diseases admitted in an intensive care unit of one Romanian center. VM Popov, L Iliescu, C Pirvu, A Grigorie, O Constantin, A Rus, D.M. Niculae Badoiu, A. Badea, M. Omer, M. Andreescu. *Clinical Lymphoma Myeloma and Leukemia* 21, S212; **impact factor 3.231 (2021)**
 61. Collaboration between Colentina Clinical Hospital and the transplant centers: A chance for life. GD GEORGESCU, F MIHAI, M OMER, V POPOV, M ANDREESCU, *Romanian Journal of medical Practice* 16 (2), 77; **impact factor 0.118 (2021)**
 62. Multimodality imaging can shift the clinical approach and prognosis of a patient: from heart failure and angina to cardiac amyloidosis - AM Chitroceanu, AI Nicula, RC Rimbasi, M Andreescu, C Popp, *Romanian Journal of Cardiology* 31 (1), 102-110 DOI: <https://doi.org/10.47803/rjc.2021.31.1.102>; **impact factor 0.09 (2021)**
 63. FLT3-ITD DNA allelic burden, but not mRNA levels, influences the biological characteristics of AML patients- Authors: Dan S Soare, Eugen Radu, Ion Dumitru, Aurora Arghir, Cristina Enache, Horia Bumbea, Ana M Vladareanu; 2021/1/29; *Revista Romana de Medicina de Laborator*; vol. 29, nr. 1, pg. 33-41; **impact factor 1.027 (2021)**
 64. CLL-370: The Prolonged Positivity of SARS-CoV-2 RNA in Chronic Lymphocytic Leukemia Patients. V Popov, M Andreescu, O Patrinoiu, M Popescu, C Despan, M Omer, *Clinical Lymphoma Myeloma and Leukemia* 20, S228; **impact factor 2.36 (2020)**
 65. Assessment of Hematologic and Coagulation Parameters As Predictive Value in COVID-19 with Unfavourable Evolution. VM Popov, L Iliescu, MI Balea, DG Georgescu, M Andreescu, H Bumbea, *Blood* 136, 13; **impact factor 22.113 (2020)**
 66. Assessment of clinical evolution of COVID-19 and neoplastic malignancies patients. V Popov, M Andreescu, M Popescu, O Patrinoiu, L Iliescu, B Mastalier, *AMERICAN JOURNAL OF HEMATOLOGY* 95, S26-S27; **impact factor 10.047 (2020) Quartile: Q1**
 67. CT-365: The Evaluation of Haematological and Biochemistry Parameters in COVID-19 Patients as a Predictive Factor for Unfavourable Evolution - V Popov, L Iliescu, M Ioan Balea, M Andreescu, M Popescu, O Patrinoiu, *Clinical Lymphoma Myeloma and Leukemia* 20, S217; **impact factor 2.36 (2020)**
 68. Novel European Asiatic Clinical, Laboratory, Molecular and Pathobiological (2015-2020 CLMP) criteria for JAK2V617F trilinear polycythemia vera (PV), JAK2exon12 PV and JAK2V617F - JJ Michiels, KH Lam, F Ten Kate, DW Kim, M Kim, V Shuvaev, F Valster, M Andreescu. *International Journal of Bone Marrow Research* 3 (1), 001-020
 69. Jan Jacques Michiels1*, King H Lam2, Fibo Ten Kate2, Dong-Wook Kim3, Myungshin Kim4, Vasily Shuvaev5, Francisca Valster6, Vincent Potters7, Wilfried Schroyens8, Mihaela Andreescu9, Adrian Trifa10, Achille Pich11 and Hendrik De Raeve12 Novel European Asiatic Clinical, Laboratory, Molecular and Pathobiological (2015-2020 CLMP) criteria for JAK2V617F trilinear polycythemia vera (PV), JAK2exon12 PV and JAK2V617F, CALR and MPL515 thrombocythemias: From Dameshek to Constantinescu-Vainchenker, Kralovics and Michiels. *Int J Bone Marrow Res.* 2020; 3: 001-020
 70. Bone marrow histology in CALR mutated thrombocythemia and myelofibrosis: Results from two cross sectional studies in 70 newly diagnosed JAK2/MPL wild type thrombocythemia patients- Authors: Jan Jacques Michiels, Yonggoo Kim, Myungshin Kim, Francisca Valster, Vincent Potters, Zwi Berneman, Alain Gadisseur, Wilfried Schroyens, Hendrik De Raeve; 2019/6/21; *International Journal of Bone Marrow Research*; vol. 2, nr. 1, pg. 064-078;
 71. HemaSphere: June 2019 - Volume 3 - Issue S1 - p 984 si prezentata la EHA 24, Amsterdam 2019, „ASSESSMENT OF PLATELET MEMBRANE ALTERATION IN PATIENTS WITH MYELOID METAPLASIA WITH MYELOFIBROSIS”- Viola Maria Popov, Cristian Matei, Bogdan Matei, Rafaela Leu, Ion Dumitru, Cristina Dobrea, Adrian P Trifa, Anamaria Iova, Madalina Begu, Mihaela Georgeta Moisescu, Tudor Savopol, Eugenia Kovacs, Vladareanu AM, Meilin Omer, Mihaela Andreescu, Oana Patrinoiu, D.M. Georgescu, Horia Bumbea
 72. CHARACTERISTICS OF DIAGNOSIS AND TREATMENT OUTCOME IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 60 YEARS-ANALYSES OF SINGLE CENTER: PB1760. - Popov, Viola; Georgescu, Daniela; Andreescu, M.; Arghir, Aurora; Dumitru, I.; Papuc, S.; Iova, A.; Begu, M.; Soare, Dan; Omer, M.; Ofiteru, G.; Patrinoiu, O.; Mihai, F.; Despan, Claudia; Popescu, M.; Balea, M.; Gogulescu, R.; Bumbea, Horia. (2019). *HemaSphere*. 3. 808- 809. 10.1097/01.HS9.0000565548.51005.fb
 73. The evaluation of oxidative status and platelet membrane function in chronic myeloproliferative neoplasms patients V Popov, C.O Matei, B.M. Matei, I. Dumitru, M. Omer, M.G. Moisescu, T. Savopol, O Patrinoiu, M. Andreescu, F. Mihai, A.M. Vladareanu, H. Bumbea, *Prezentare poster: la XXXIst International Symposium on Technological Innovations in Laboratory Hematology*, 10-12 mai 2018, Bruxelles, Belgia, PosterNo290, http://www.islh.org/2018/program.php?page=program&displayday=2&pads=&start_range=&start_interval=&changing_days=yes&hide_details=
 74. Assessment of Changes of Membrane Properties and Platelets Function in Patients with Chronic Myeloid Leukaemia- Viola Popov, Vladareanu ANA Maria, Matei MIRCEA Bogdan, Matei Christien Oktaviani, Mihaela Georgeta Moisescu, Kovacs Eugenia, Meilin Omer, Mihaela Andreescu, Oana Patrinoiu, Savopol Tudor, Horia Bumbea - *Blood* 130 (Supplement 1), 4846-4846; **impact factor 13.164 (2017)**
 75. Aggressive paraneoplastic encephalo-myelo-polyradiculoneuritis with anti-VGCC antibodies and anaplastic lymphoma in a 17-year-old patient: A case report- Authors: G-C Gaciu, R Mihailescu, L Dumitrescu, P Carmen, I Militaru, M Andreescu, L Iliescu, BO Popescu, R Tanasescu, J Orban; 2017/7/1; *European Journal of Neurology*; vol. 24, pg. 440-440, editor Wiley; **impact factor 3.988 (2017)**
 76. Genomic abnormalities in acute myeloid leukemia with normal karyotype- Authors: Aurora Arghir, Sorina Mihaela Papuc, Andreea-Cristina Tutulan-Cunita, Raluca Colesniuc, Ioana Borcan, Silvana Angelescu, Mihaela Andreescu, Diana Cisleanu, Ana-Maria Vladareanu, Horia Bumbea; 2017/6/29; *Molecular Cytogenetics conference*; vol. 10, editor Biomed Central LTD; **impact factor 1.455 (2017)**
 77. THE IMPORTANCE OF PLATELET MEMBRANE FLUIDITY AND OXIDATIVE STRESS IN THROMBOTIC

- COMPLICATIONS ACQUIRED BY CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS - VM Popov, M Andreescu, M Omer, A Trifa, F Mihai, C Dragan, O Patrinoiu, et al - HAEMATOLOGICA 102, 649-650; **impact factor 9.090 (2017)**
78. "THROMBOTIC COMPLICATIONS IN HEMATOLOGIC MALIGNANCIES" - M Popescu, D Georgescu, M Balea, M Tevet, O Patrinoiu, M Murat, HAEMATOLOGICA 101, 871-872; **impact factor 7.702 (2016)**
 79. "THE IMPORTANCE OF OXIDATIVE STRESS IN ABNORMALITIES OF PLATELET FUNCTION. THE RETROSPECTIVE STUDY IN CHRONIC MYELOID LEUKEMIA AND MYELODISPLASTIC SYNDROME PATIENTS" - Popov Viola, Minodora Iordache, Ana Maria Vladareanu, Mihaela Tevet, Thrombosis Research 141, SUPPL 1:89 May 2016; **impact factor 2.320 (2016)**
 80. „The analyses of efficacy and tolerability of ruxolitinib in myelofibrosis patients-our experience” - VM Popov, M Tevet, M Murat, CV Dragan, DG Georgescu, OFG Patrinoiu - Conferinta internationala a ISH Glasgow 2016, publicat in BRITISH JOURNAL OF HAEMATOLOGY 173, 129-129; **impact factor 5.401 (2016) Quartile: Q1**
 81. Hypereosinophilic syndromes FIP1L1/PDGFR fusion gene NEGATIVE-hematological remission on imatinib mesilate: 522 - D Georgescu, O Patrinoiu, V Popov, M Tevet, M Balea, S Zurac, C Dobrea, British Journal of Haematology 173, 175-176; **impact factor 5.401 (2016) Quartile: Q1**
 82. Hematological malignancies in HIV/AIDS- Authors: DG Georgescu, MT Tevet, MB Balea, CD Dragan, MM Murat, SS Schiopu; 2016/4/1; British Journal of Haematology; vol. 173, pg. 173-174; editor Wiley-Blackwell; **impact factor 5.401 (2016) Quartile: Q1**
 83. Acute myeloid leukemia in a 19 year old patient previously treated for osteosarcoma- case report: AB77- Authors: C Dragan, M Murat, D Georgescu, M Tevet, F Mihai; 2016/3; Bone Marrow Transplantation Journal; vol. 51, pg. S599; **impact factor 3.636 (2016)**
 84. "Acute myeloid leukemia in a 19 years old patient previously treated for osteosarcoma – case report and review of the literature" - Drăgan C., Meilin Murat, Trifa A., Tevet Mihaela. Therapeutics, Pharmacology and Clinical Toxicology. Vol XIX, Number 4, pg 165
 85. 191 The experience of a single center of Hematology in the treatment with hypomethylating agents- Authors: D. Georgescu, M. Popescu, M. Tevet, O. Patrinoiu, M. Murat, A. Ciuhu; 2015/4/1; Leukemia Research Journal; vol. 39, pg. S95-S96, editor Pergamon; **impact factor 2.351 (2015)**
 86. Terapia antiemetica in afectiunile maligne hematologice si non-hematologice- autori: Daniela G Georgescu, Mihaela Popescu, Mihaela Tevet, Meilin Murat, Gabriela Rahnea Nita, Anda Natalia Ciuhu; 2014/12/1; jurnal Oncolog-Hematolog; nr. 29;
 87. „Antiemetic therapy in hematologic and nonhematologic malignancies” - Daniela, Georgescu G.; Mihaela, Popescu; Mihaela, Tevet; et all, Therapeutics Pharmacology and Clinical Toxicology. Volume XVIII Issue 3, September 2014
 88. „Variation and distribution of mast cells in benign and malignant lymphoid lesions” - M. D. Cioplea, S. Zurac, L. Sticlaru, S. Duțulescu, A. Stan, C. Popp, A. Oniga, G. Pop, M. Tevet, V. Chițu, F. Stăniceanu,. prezentare orala, publicat in 26th European Congress of Pathology. Virchows Archiv, 2014;465, Supplement 1:278
 89. Remisiune completa de boala obtinuta in cazul unei paciente cu dubla neoplazie: limfom folicular si tumora renala Grawitz, diagnostic simultan- autori: Oana Patrinoiu, Dana Georgescu, Marius Balea, Sabina Zurac, Mihaela Tevet; 2013/1/1; jurnal Oncolog-Hematolog; nr 22
 90. Clinical significance of JAK2 mutation in patients with chronic MPN and evaluation of it as a risk factor for hemorrhagic complication in these disorders- Authors: M Tevet, A Lupu, C Saguna, C Dragan, A Colita, G Barca; 2012/7/16; Haematologica conference; vol. 97, pg. 636-636, editor Ferrata Storti Foundation; **impact factor 5.945 (2012)**
 91. The role of JAK2-V617F mutation in leukemic transformation of myeloproliferative neoplasms- Authors: M Tevet, A Lupu, C Saguna, C Dragan, A Colita, G Barca; 2012/7/16; Haematologica conference; vol. 97, pg. 633-633, editor Ferrata Storti Foundation; **impact factor 5.935 (2012)**
 92. Myelodysplastic syndromes: challenging disorders for cytogeneticists and hematologists- Authors: Aurora Arghir, Sorina Mihaela Chiriac, Ana Maria Vladareanu, Mihaela Closca, Horia Bumbea, Gabriela Mocanu, Nicoleta Berbec, Loana Borcan, Andreea Tutulan-Cunita; 2011/6/1; Chromosome Research conference; vol. 19, pg. S159-S160; editor Springer; **impact factor 3.087 (2011)**
 93. „NEW MOLECULAR MARKERS IN DIAGNOSIS OF SPLENIC LYMPHOMAS” - M. Closca- Gheorghiu, G. Ofiteru, A.R. Lupu, C. Saguna, O. Ciocan, A. Colita, A. Ciobanu, C. Mitrescu, E. Coles; Haematologica 2009; 94(s2); **impact factor 4.485 (2009)**
 94. „New molecular markers in diagnosis of splenic lymphomas” - Autori: Anca-Roxana LUPU, MD, PhDa; Mihaela CLOSCA-GHEORGHIU, MD; Geanina Carla OFITERU, MDa; Elena COLES, MDa; Oana CIOCAN, MDa; Carmen SAGUNA, MDa; Anca CIOBANU, MDa; Ligia BARBARII, MD, Hematology Clinic, "Coltea" Clinical Hospital, Bucharest, Romania, Mædica A Journal of Clinical Medicine, Volume 4 No.1 2009 19 **Quartile: Q1**
 95. „To horizon: The use of synthetic O blood group in practical substitutive therapy” - Autori: Anca Roxana LUPUa, MD, PhD, Anca CIOBANUb, MD, Oana CIOCANa, MD, Mihaela CLOSCA-GHEORGHIU, MD, Carmen SAGUNAA, MD, Irina CARAUSUc, MD "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, MÆDICA - a Journal of Clinical Medicine, Volume 2(5) No.2 2007 **Quartile: Q1**
 96. Hematologia in practica medicala, Editura Universitatii "Carol Davila" Bucuresti,2005; Autori: Prof. dr. Anca Roxana Lupu, co-autori : Oana Ciocan, Anca Ciobanu, Mihaela Closca-Gheorghiu, Laura Bleotu, Cristina Ciufu, Diana Cisleanu
 97. COVID-19-associated rhinocerebral mucormycosis: an increasingly frequent finding with various clinical manifestations and necessity for critical therapeutic intervention- Authors: M. Andreescu, H. Mocanu, A.-I. Mocanu, C. Moldovan; Medical Science: Trends and Innovations Journal, pg. 70
 98. Andreescu M. Correlation Between Maternal-Fetus Interface and Placenta-Mediated Complications. Cureus. 2024 Jun 16;16(6):e62457. doi: 10.7759/cureus.62457. PMID: 38882223; PMCID: PMC11180486; **impact factor 1.0 (2024)**
 99. Evaluation of the impact of COVID-19 infection on the evolution and prognosis of patients with acute leukemia- Authors: V. Popov, M. Omer, L. Iliescu, M. Andreescu, D. Georgescu, F. Mihai, M. Popescu, C. Pirvu, A. Grigorie, A. Rus, M. D. Badoiu Niculae, O. Constantin, A. Badea, A. Calen, O. Patrinoiu, S. Ciortan, C. Despan, G. Ofiteru,

- S. Ion, M. Balea, H. Bumbea; Hematology-Oncology International Journal
100. Correlation between pro- and anti-apoptotic gene expression and telomerase activity in B-cell lymphomas- Authors: C. D. Goia, A. R. Lupu, C. Bleotu, C. Antipa, L. Velt, E. Popa, G. Constantinescu, M. Closca, G. Anton; 2008;
101. „NEWS IN CYTOGENETIC AND MOLECULAR DIAGNOSIS TEL-JAK-2 FUSION AS A MODEL FOR HYBRID ONCOGENES” - Mihaela Closca-Gheorghiu, AR Lupu, Oana Ciocan, Anca Ciobanu, Aurora Arghir, Agripina Lungeanu - Maedica a Journal of Clinical Medicine vol 1 - nr. 3/2006 pg 46-53 **Quartile: Q1**
102. Herbal treatments for chronic rhinosinusitis- a narrative comparison of Western knowledge to Eastern European traditional remedies and oriental traditional medicine- Authors: A.-I. Mocanu, H. Mocanu, M. Lupascu, A.-C. Neagu, M. Andreescu, R. M. Nemes; IJMPR 2024, 8(9), 01-24; ISSN:2319-5878; International Journal of Modern Pharmaceutical Research; SJIF **Impact Factor: 6.669 (2024)**

Articole indexate Web of Science:

1. Intraventricular mass in a 52-year-old woman - Author(s): Felix Mircea Brehar, Alexandra Mihaela Patrascan, Mihaela Andreescu, Laura-Gabriela Tirlea, Sabina-Loredana-Georgiana Olteanu, Simon Schallenberg, Mihnea P. Dragomir, George E. D. Petrescu; 2025. E70003. <https://onlinelibrary.wiley.com/doi/10.1111/bpa.70003>. **Impact Factor of 5.8 (2023); Quartile: Q1**
2. Mihaela Andreescu, Alina Tanase, Bogdan Andreescu, Cosmin Moldovan; A review of Immunological Evaluation of Patients with Recurrent Spontaneous Abortion (RSA); 2025/1/17; International Journal of Molecular Sciences, vol. 26, nr. 2, pg. 785, editor MDPI. **Impact Factor of 4.9 (2023); Quartile: Q1**
3. Evaluation of Prognostic Factors Involved in the Evotion of Secondary Acute Leukemia Patients- Author(s): Meilin Omer, Viola Maria Popov, Horia Bumbea, Mihaela Andreescu, Maria Bacanu, Mihaela Popescu, Geanina Ofiteru, Lidia Felicia Mihai, Oana Patrinoiu, Ion Dumitru, Dan Sebastian Soare, Aurora Arghir, Ana Maria Vladareanu; 2024/11/5; Blood; vol. 144, pg. 6141; **Impact factor 21.0 (2024). Quartile: Q3**
4. MM-121 Extramedullary Multiple Myeloma- Report of a Case Manifested as a Retroperitoneal Mass and Cholestatic Syndrome- Authors: Viola Maria Popov, Dan Constantinescu, Gabriel Constantinescu, Bogdan Diaconescu, Valentin Enache, Camelia Dobrea, Mirela Voicu, Mihaela Andreescu; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal; vol. 24,pg. S537; editor Elsevier; **Impact factor 2.7 (2024). Quartile: Q3**
5. AML-546 Particularities of Evolution in Acute Leukemia Patients with a History of Neoplasms- Retrospective Analysis- Authors: Meilin Omer, Viola Maria Popov, Mihaela Andreescu, Horia Bumbea, Oana Patrinoiu, Mihaela Popescu, Felicia Mihai, Geanina Ofiteru, Aurora Arghir, Dan Soare, Ion Dumitru, Ana Maria Vladareanu; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal; vol. 24, pg. S319-S320; editor Elsevier; **Impact factor 2.7 (2024). Quartile: Q3**
6. MPN-123 Complex Clonal Evolution in a Patient with Advanced Myelofibrosis Exhibiting Bone Marrow Hypercellularity and Chromosomal Anomalies- Authors: Maria Bacanu, Viola Maria Popov, Dumitru Jordan, Camelia Dobrea, Mirela Voicu, Dan Constantinescu, Mihaela Andreescu, Meilin Omer; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal, vol. 24; pg. S416; editor Elsevier; **Impact factor 2.7 (2024). Quartile: Q3**
7. A primary Pulmonary Determination- A rare Form of Marginal B-Cell Lymphoma: A Case Report- Author(s): Viola Maria Popov, Mirela Voicu, Dan Costantinescu, Felicia Mihai, Alexandru Dragos Sion, Horia Bumbea, Mihnea Dan Davidescu, Camelia Dobrea, Mihaela Andreescu; 2024/9/1; Clinical Lymphoma Myeloma and Leukemia journal; vol. 24, pg. S221; editor Elsevier; **Impact factor 2.7 (2024). Quartile: Q3**
8. Andreescu M. Correlation Between Maternal-Fetus Interface and Placenta-Mediated Complications. Cureus. 2024 Jun 16;16(6):e62457. doi: 10.7759/cureus.62457. PMID: 38882223; PMCID: PMC11180486; **Impact factor 1.0 (2024). Quartile: Q3**
9. Andreescu M, Andreescu B. A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery. Cureus. 2024 Mar 12;16(3):e56008. doi: 10.7759/cureus.56008. PMID: 38606222; PMCID: PMC11007487; **Impact factor 1.0 (2024). Quartile: Q3**
10. Andreescu M. Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies. Cureus. 2024 Jan 4;16(1):e51662. doi: 10.7759/cureus.51662. PMID: 38179322; PMCID: PMC10766007; **Impact factor 1.0 (2024). Quartile: Q3**
11. Andreescu M. Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies. Cureus. 2024 Jan 10;16(1):e52050. doi: 10.7759/cureus.52050. PMID: 38344573; PMCID: PMC10857843; **Impact factor 1.0 (2024). Quartile: Q3**
12. Andreescu M. Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies. Cureus. 2024 Jan 4;16(1):e51662. doi: 10.7759/cureus.51662. PMID: 38179322; PMCID: PMC10766007; **Impact factor 1.0 (2024). Quartile: Q3**
13. Andreescu M, Moldovan C, Lespezeanu DA, Mocanu AI, Schipor MA, Mocanu H. COVID-19-Associated Rhinocerebral Mucormycosis, an Incidental Finding or a Matter of Concern - Mixed-Method Systematic Review. Infect Drug Resist. 2024 Jan 31;17:387-402. doi: 10.2147/IDR.S445458. PMID: 38312523; PMCID: PMC10838509; **Impact factor 2.9 (2024). Quartile: Q2**
14. Plotogea, M.; Zgura, A.; Mehedințu, C.; Scurtu, F.; Petca, A.; Varlas, V.N.; Bors, R.G.; Edu, A.; Ionescu, O.-M.; Andreescu, M.; et al. Women's Sexual Dysfunctions Following Stem Cell Transplant and the Impact on Couple Relationship. Life 2024, 14, 35. <https://doi.org/10.3390/life14010035>. **Impact factor 3.2 (2023). Quartile: Q1**
15. Andreescu M. Molecular Insights Into the Role of Gut Microbiota in Antibiotic Therapy Selection and Resistance Mitigation. Cureus. 2023 Dec 11;15(12):e50318. doi: 10.7759/cureus.50318. PMID: 38089944; PMCID: PMC10714069; **Impact factor 1.0 (2023). Quartile: Q3**
16. Andreescu M (November 30, 2023) Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and

Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy. *Cureus* 15(11): e49696. doi:10.7759/cureus.49696; **Impact factor 1.0 (2023). Quartile: Q3**

17. Andreescu, M.; Popov, V.; COVID-19-Trigger for Chronic Myeloid Leukemia Evolution?, *Clinical Lymphoma Myeloma and Leukemia*, September 2023. 23:S333; DOI:[10.1016/S2152-2650\(23\)01124-2](https://doi.org/10.1016/S2152-2650(23)01124-2); **Impact factor 2.7 (2023). Quartile: Q3**
18. Andreescu, M. (2023). The Impact Of the Use Of Immunosuppressive Treatment After An Embryo Transfer In Increasing The Rate Of Live Birth. *Frontiers Med.*, (10). <https://doi.org/10.3389/fmed.2023.116787>. **Impact factor: 5.058 (2023) Quartile: Q1**
19. Andreescu, M. Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies. *Life* 2023, 13, 1272. <https://doi.org/10.3390/life13061272>. **Impact factor: 3.257 (2023). Quartile: Q1**
20. Andreescu, M.; Berbec, N.; Tanase, A.D. Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia. *J. Clin. Med.* 2023, 12, 2731. <https://doi.org/10.3390/jcm12072731>, **Impact factor: 4,965 (2023). Quartile: Q1**
21. Andreescu, M., Frîncu F, Plotogea M, Mehedintu C. Recurrent Abortion and the Involvement of Killer-Cell Immunoglobulin-like Receptor (KIR) Genes, Activated T Cells, NK Abnormalities, and Cytokine Profiles. *J Clin Med.* 2023 Feb 8;12(4):1355. doi: 10.3390/jcm12041355. PMID: 36835892; PMCID: PMC9968158., **Impact factor: 4,965 (2023). Quartile: Q1**
22. Andreescu M, Zurac S, Lacatusu A, Tudor AT, Ilie N, Tirlea LG, et al. Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin's lymphoma. *Rev Romana Med Lab.* 2023;31(1):59-64. DOI:10.2478/rrlm-2023-0007, **Impact factor 1.027 (2023). Quartile: Q4**
24. Poster: CLL-033 Is Covid-19 infection a Trigger for Progression of CLL?- Authors: Viola Popov, Horia Bumbea, Mihaela Andreescu, Geanina Ofiteru, Felicia Mihai, Mihaela Popescu, Oana Patrinoiu, Daniela Georgescu, Claudia Despan, Meilin Omer; 2022/9/21; *Clinical Lymphoma, Myeloma & Leukemia journal*; vol. 22, pg. S140; **Impact factor 2.822 (2022) Quartile: Q3**
25. The importance of the long Covid-19 in the evolution of patients with neoplasms. V Popov, M Andreescu, C Pirvu, A Grigorie, O Constantin, A Calen, *Journal of Clinical Oncology* 40 (16_suppl), e18647-e18647; **Impact factor 50.717 (2022). Quartile: Q1**
26. AML-168: the assessment of COVID-19 evolution in patients with oncological diseases admitted in an intensive care unit of one Romanian center. VM Popov, L Iliescu, C Pirvu, A Grigorie, O Constantin, A Rus, M. Andreescu. *Clinical Lymphoma Myeloma and Leukemia* 21, S285-S286; **Impact factor 3.231 (2021). Quartile: Q3**
27. Assessment of Hematologic and Coagulation Parameters As Predictive Value in COVID-19 with Unfavourable Evolution. VM Popov, L Iliescu, MI Balea, DG Georgescu, M Andreescu, H Bumbea, *Blood* 136, 13; **Impact factor 22.113 (2020). Quartile: Q1**
28. CLL-370: The Prolonged Positivity of SARS-CoV-2 RNA in Chronic Lymphocytic Leukemia Patients. V Popov, M Andreescu, O Patrinoiu, M Popescu, C Despan, M Omer, *Clinical Lymphoma Myeloma and Leukemia* 20, S228; **Impact factor 2.36 (2020). Quartile: Q3**
29. Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma—Romanian Experience, Authors: Alina D.Tanase, Andrei Colita, Oana G. Craciun, Lavinia Lipan, Zsofia Varady, Laura Stefan, Adela Ranete, Sergiu Pasca, Horia Bumbea, Mihaela Andreescu, Viola Popov, Alexandru Bardas, Daniel Coriu, Anca Roxana Lupu, Ciprian Tomuleasa, Anca Colita and Olivier Hermine - *J Clin Med.* 2020 Jul 28;9(8):2417.doi: 10.3390/jcm9082417; **Impact factor 3.303 (2020). Quartile: Q1**
30. Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence, Horia Bumbea, MD PhD, Ambroise Marçais, MD PhD, Daniel Coriu, MD PhD, Alina Daniela Tanase, MD PhD, Andrei Colita, MD PhD, Alexandru Bardas, MD, Anca Roxana Lupu, MD PhD, Ana-Maria Vladareanu, MD PhD, Minodora Cezarina Onisai, MD PhD, Viola Maria Popov, MD PhD MSc, Iuliana Iordan, MD, Magda Diana Cisleanu, MD PhD, Daniela Stefania Vasile, MD PhD, Cristina Maria Ciufu, MD PhD, Zsofia Varady, MD PhD, Oana Gabriela Craciun, MD, Daniela Georgeta Georgescu, MD PhD, Mihaela Andreescu, MD PhD, Cristina Mambet, MD, Carmen C. Diaconu, PhD, Laura Necula, PhD, Monica Bunaciu, Adriana Necula, Stefan N Constantinescu, MD PhD, Olivier Hermine, MD PhD, *Blood* (2019) 134 (Supplement_1): 5288; **Impact factor 17.543 (2019). Quartile: Q1**
31. The Importance of CD36 Expression in Evaluation of Thrombotic Risk in Patients with Myeloproliferative Neoplasms- Viola Popov, MD PhD MSc, Meilin Omer, MD, Adrian Trifa, MD PhD, ION Dumitru, MD, Oana Patrinoiu, MD PhD, Mihaela Andreescu, MD PhD, Horia Bumbea, MD PhD -*Blood* (2018) 132 (Supplement 1): 4989., <https://doi.org/10.1182/blood-2018-99-115349>; **Impact factor 15.132 (2018). Quartile: Q1**
32. „Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia” Authors: Adrian P. Trifa, Claudia Banescu, Cristian M. Voina, Stefana Popa, Tunde Torok-Vistai, Anca S. Bojan, Delia Dima, Mihnea Zdrenghea, Bogdan Fetica, Simona Visan, Ciprian Tomuleasa, Andrada Parvu, Laura Urian, Bogdan Pop, Viola M. Popov, Mihaela Andreescu, Radu A. Popp.; published in *Blood Cells, Molecules and Diseases* 7392018) 45-46; **Impact factor 1.836 (2018). Quartile: Q2**

33. „The evaluation of oxidative status and platelet membrane function in chronic myeloproliferative neoplasms patients” la XXXIst International Symposium on Technological Innovations in Laboratory Hematology, 10-12 mai 2018, Bruxelles, Belgia, autori: V Popov, C.O Matei, B.M. Matei, I. Dumitru, M. Omer, M.G. Moiescu, T. Savopol, O Patrinoiu, M. Andreescu, F. Mihai, A.M. Vladareanu, H. Bumbea, Poster No 290. **Impact factor 1.42 (2018). Quartile: Q3**
34. „MECOM, HBS1L-MYB, THRB-ARB, JAK2 and TERT polymorphism defining the genetic predisposition to myeloproliferative neoplasms: study on 939 patient” Authors: Adrian P. Trifa, Cllaudiia Banescu, Anca S. Bojan, Cristian M. Voina, Stefana Popa, Simona Visan, Alina D. Ciubean, Florin Tripon, Delia Dima, Viola M. Popov, Stefan C. Vesa, Mihaela Andreescu, Tunde Torok-Vistai, Romeo G. Mihaila, Nicoleta Berbec, Ioan Macarie, Andrei Colita, Maria Iordache, Alina C. Catana, Marius F. Farcas, Ciprian Tomuleasa, Kinga Vasile, Cristina Truica; published in American Journal of Hematology 2018 Jan;93(1):100-106. doi: 10.1002/ajh.24946. Epub 2017 Nov 10; **Impact factor 5.303 (2018). Quartile: Q1**
35. Assessment of Changes of Membrane Properties and Platelets Function in Patients with Chronic Myeloid Leukaemia- Viola Popov, Vladareanu ANA Maria, Matei MIRCEA Bogdan, Matei Christien Oktaviani, Mihaela Georgeta Moiescu, Kovacs Eugenia, Meilin Omer, Mihaela Andreescu, Oana Patrinoiu, Savopol Tudor, Horia Bumbea - Blood 130 (Supplement 1), 4846-4846; **Impact factor 13.164 (2017). Quartile: Q1**
36. Aggressive paraneoplastic encephalo-myelo-polyradiculoneuritis with anti-VGCC antibodies and anaplastic lymphoma in a 17-year-old patient: A case report- Authors: G-C Gaciu, R Mihailescu, L Dumitrescu, P Carmen, I Militaru, M Andreescu, L Iliescu, BO Popescu, R Tanasescu, J Orban; 2017/7/1; European Journal of Neurology; vol. 24, pg. 440-440, editor Wiley; **Impact factor 3.988 (2017). Quartile: Q1**
37. Genomic abnormalities in acute myeloid leukemia with normal karyotype- Authors: Aurora Arghir, Sorina Mihaela Papuc, Andreea-Cristina Tutulan-Cunita, Raluca Colesniuc, Ioana Borcan, Silvana Angelescu, Mihaela Andreescu, Diana Cisleanu, Ana-Maria Vladareanu, Horia Bumbea; 2017/6/29; Molecular Cytogenetics conference; vol. 10, editor Biomed Central LTD. **Impact factor 1.167 (2017). Quartile: Q3**
38. THE IMPORTANCE OF PLATELET MEMBRANE FLUIDITY AND OXIDATIVE STRESS IN THROMBOTIC COMPLICATIONS ACQUIRED BY CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS - VM Popov, M Andreescu, M Omer, A Trifa, F Mihai, C Dragan, O Patrinoiu, et all - HAEMATOLOGICA 102, 649-650; **Impact factor 9.090 (2017). Quartile: Q1**
39. „Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms” Trifa AP1,2, Bănescu C3, Dima D4, Bojan AS4,5, Tevet M6, Moldovan VG3, Vesa C7, Murat M6, Pop IV1, Skrypnik C8, Popp RA1. - Hematology Journal. 2016 Oct; 21(9):520-5. doi: 10.1080/10245332.2016.1163889. Epub 2016 Mar 30; **Impact factor 1.385 (2016). Quartile: Q3**
40. „TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.” - Trifa AP, Bănescu C, TevetM, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA. British Journal of Haematol. 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. Epub 2016 Apr 7; **Impact factor 5.401 (2016). Quartile: Q1**
41. “THROMBOTIC COMPLICATIONS IN HEMATOLOGIC MALIGNANCIES” - M Popescu, D Georgescu, M Balea, M Tevet, O Patrinoiu, M Murat, HAEMATOLOGICA 101, 871-872; **Impact factor 7.702 (2016). Quartile: Q1**
42. “THE IMPORTANCE OF OXIDATIVE STRESS IN ABNORMALITIES OF PLATELET FUNCTION. THE RETROSPECTIVE STUDY IN CHRONIC MYELOID LEUKEMIA AND MYELODISPLASTIC SYNDROME PATIENTS” - Popov Viola, Minodora Iordache, Ana Maria Vladareanu, Mihaela Tevet, Thrombosis Research 141, SUPLM 1:89 May 2016; **Impact factor 2.320 (2016). Quartile: Q1**
43. Hypereosinophilic syndromes FIP1L1/PDGFR fusion gene NEGATIVE-hematological remission on imatinib mesilate: 522 - D Georgescu, O Patrinoiu, V Popov, M Tevet, M Balea, S Zurac, C Dobra, British Journal of Haematology 173, 175-176; **Impact factor 5.401 (2016). Quartile: Q1**
44. Hematological malignancies in HIV/AIDS- Authors: DG Georgescu, MT Tevet, MB Balea, CD Dragan, MM Murat, SS Schiopu; 2016/4/1; British Journal of Haematology; vol. 173, pg. 173-174; editor Wiley-Blackwell; **Impact factor 5.401 (2016). Quartile: Q1**
45. „The analyses of efficacy and tolerability of ruxolitinib in myelofibrosis patients-our experience” - VM Popov, M Tevet, M Murat, CV Dragan, DG Georgescu, OFG Patrinoiu - Conferinta internationala a ISH Glasgow 2016, publicat in BRITISH JOURNAL OF HAEMATOLOGY 173, 129-129; **Impact factor 5.401 (2016). Quartile: Q1**
46. Acute myeloid leukemia in a 19 year old patient previously treated for osteosarcoma- case report: AB77- Authors: C Dragan, M Murat, D Georgescu, M Tevet, F Mihai; 2016/3; Bone Marrow Transplantation Journal; vol. 51, pg. S599; **Impact factor 3.636 (2016). Quartile: Q1**
47. „The experience of a single center of hematology in the treatment with hypomethylating agents.” - Daniela Georgescu, Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - Cel de-al 13- lea Simpozion in SMD Washington, USA, aprilie/mai 2015. **Impact factor 2.351 (2015).**

48. „Multiple intestinal Lymphoma” - Mastalier B, Deaconescu V, Elaiah W, Drăghici C, Popp C, Zurac S, Balea M, Tevet M, Botezatu C. Rom J Intern Med. 2015 Jan-Mar;53(1):73-8; **Impact factor 0.683 (2015). Quartile: Q3**
49. „CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.” - Trifa AP, Popp RA, Cucuianu A, Bănescu C, Tevet M, Martin B, Murat M, Vesa SC, Dima D, Căndea M, Militaru MS, Pop IV. British Journal of Haematol. 2015 Jan; 168(1): 151-3. doi: 10.1111/bjh.13076. Epub 2014 Aug 8; **Impact factor 4.711 (2015). Quartile: Q1**
50. „Variation and distribution of mast cells in benign and malignant lymphoid lesions” - M. D. Cioplea, S. Zurac, L. Sticlaru, S. Duțulescu, A. Stan, C. Popp, A. Oniga, G. Pop, M. Tevet, V. Chițu, F. Stăniceanu, prezentare orală, publicat în 26th European Congress of Pathology. Virchows Archiv, 2014;465, Supplement 1:278. **Impact factor 2.651 (2014). Quartile: Q2**
51. Clinical significance of JAK2 mutation in patients with chronic MPN and evaluation of it as a risk factor for hemorrhagic complication in these disorders- Authors: M Tevet, A Lupu, C Saguna, C Dragan, A Colita, G Barca; 2012/7/16; Haematologica conference; vol. 97, pg. 636-636, editor Ferrata Storti Foundation; **Impact factor 5.935 (2012). Quartile: Q1**
52. The role of JAK2-V617F mutation in leukemic transformation of myeloproliferative neoplasms- Authors: M Tevet, A Lupu, C Saguna, C Dragan, A Colita, G Barca; 2012/7/16; Haematologica conference; vol. 97, pg. 633-633, editor Ferrata Storti Foundation; **Impact factor 5.935 (2012). Quartile: Q1**
53. “Immunotherapy with Rituximab in Follicular Lymphomas” - Carmen SAGUNA, MD, a Ileana Delia MUT, MD, PhD, Anca Roxana LUPU, MD, PhD, a Mihaela TEVET, MD, SR, a Horia BUMBEA, MD, PhD, b and Cornel DRAGANA, Maedica 2011, 2011 April; 6(2): 100-108.

Articole publicate in jurnale de specialitate si indexate Pubmed, Research Gate etc:

1. „TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.” - Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Patrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA. *British Journal of Haematol.* 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. Epub 2016 Apr 7; **impact factor 5.401 (2016)**. **Quartile: Q1**
2. „CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.” - Trifa AP, Popp RA, Cucuianu A, Bănescu C, Tevet M, Martin B, Murat M, Vesa SC, Dima D, Căndea M, Militaru MS, Pop IV. *British Journal of Haematol.* 2015 Jan; 168(1): 151-3. doi: 10.1111/bjh.13076. Epub 2014 Aug 8; **impact factor 4.711 (2015)**. **Quartile: Q1**
3. „Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders.” - Tevet M, Ionescu R, Dragan C, Lupu AR. *Maedica (Bucharest)*. 2015 Mar;10(1):27- 32.
4. „The analyses of efficacy and tolerability of ruxolitinib in myelofibrosis patients-our experience” - VM Popov, M Tevet, M Murat, CV Dragan, DG Georgescu, OFG Patrinoiu - Conferinta internationala a ISH Glasgow 2016, publicat in BRITISH JOURNAL OF HAEMATOLOGY 173, 129-129; **impact factor 5.401 (2016)**. **Quartile: Q1**
5. "Pathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm" - Viola Maria Popov, Mihaela Andreescu, Ana Maria Vladareanu, Ion Dumitru, Felicia Mihai, Horia Bumbea - *Hematology and Transfusion International Journal*, 6(2) 50-53, 2018, ISSN: 2469-2778.
6. „Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia” Authors: Adrian P. Trifa, Claudia Banescu, Cristian M. Voina, Stefana Popa, Tunde Torok-Vistai, Anca S. Bojan, Delia Dima, Mihnea Zdrenghea, Bogdan Fetica, Simona Visan, Ciprian Tomuleasa, Andrada Parvu, Laura Urian, Bogdan Pop, Viola M. Popov, Mihaela Andreescu, Radu A. Popp.; published in *Blood Cells, Molecules and Diseases* 73(2018) 45-46; **impact factor 1.836 (2018)**. **Quartile: Q3**
7. „MECOM, HBS1L-MYB, THRB-ARB, JAK2 and TERT polymorphism defining the genetic predisposition to myeloproliferative neoplasms: study on 939 patient” Authors: Adrian P. Trifa, Claudiia Banescu, Anca S. Bojan, Cristian M. Voina, Stefana Popa, Simona Visan, Alina D. Ciubean, Florin Tripon, Delia Dima, Viola M. Popov, Stefan C. Vesa, Mihaela Andreescu, Tunde Torok-Vistai, Romeo G. Mihaila, Nicoleta Berbec, Ioan Macarie, Andrei Colita, Maria Iordache, Alina C. Catana, Marius F. Farcas, Ciprian Tomuleasa, Kinga Vasile, Cristina Truica; published in *American Journal of Hematology* 2018 Jan;93(1):100-106. doi: 10.1002/ajh.24946. Epub 2017 Nov 10; **impact factor 5.303 (2018)**. **Quartile: Q1**
8. „Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms” Trifa AP1,2, Bănescu C3, Dima D4, Bojan AS4,5, Tevet M6, Moldovan VG3, Vesa C7, Murat M6, Pop IV1, Skrypnik C8, Popp RA1. - *Hematology Journal*. 2016 Oct; 21(9):520-5. doi: 10.1080/10245332.2016.1163889. Epub 2016 Mar 30; **impact factor 1.385 (2016)**.
9. „2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications” - Jan Jacques MICHIELS; Mihaela TEVET, Adrian Trifa, Emilia Niculescu-Mizil, Anca Lupu, Ana Maria Vladareanu, Horia Bumbea, Anca Ilea, Camelia Dobrea, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Meilin Murat, Cornel Dragan, Felicia Mihai, Sabina Zurac, Silvana Angelescu, Anamaria Iova, Alina Popa, Rodica Gogulescu, Viola Popov - *MAEDICA - a Journal of Clinical Medicine* 2016; 11(5): 5-25. **Quartile: Q1**
10. Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma—Romanian Experience, Authors: Alina D.Tanase, Andrei Colita, Oana G. Craciun, Lavinia Lipan, Zsofia Varady, Laura Stefan, Adela Ranete, Sergiu Pasca, Horia Bumbea, Mihaela Andreescu, Viola Popov, Alexandru Bardas, Daniel Coriu, Anca Roxana Lupu, Ciprian Tomuleasa, Anca Colita and Olivier Hermine - *J Clin Med*. 2020 Jul 28;9(8):2417.doi: 10.3390/jcm9082417; **impact factor 3.303 (2020)**.
11. „Predictive value of hematologic and coagulation parameters in assessment of severity and evolution of COVID-19 patients” -Viola Maria Popov, Lelia Iliescu, Marius Ioan Balea, Horatiu Ioani, Mihaela Andreescu, Daniela Georgescu, Catalina Parvu, Andra Grigorie, Oana Constantin, Ana Rus, Adriana Badea, Dana Mihaela Badoiu Niculae, Claudia Despan, Meilin Omer, Geanina Ofiteru, Oana Patrinoiu, Mihaela Popescu, Marius Lucian Balea, Felicia Mihai, Silvia Ion, Horia Bumbea, Valentin Nedelcu, Daniela Gologanu, Gabriel Popescu, Adriana Hristea, Elisabeta Stoica, Bogdan Mastalier, Remus Gabriel Mihalcea, Bogdan Diaconescu - *Merit Research Journal of Medicine and Medical Sciences* (ISSN: 2354-323X) Vol. 8(10), pp. 605-615, October, 2020; **impact factor 0.678 (2020)**.

12. „Multiple intestinal Lymphoma” - Mastalier B, Deaconescu V, Elaiah W, Drăghici C, Popp C, Zurac S, Balea M, Tevet M, Botezatu C. Rom J Intern Med. 2015 Jan-Mar;53(1):73-8; **impact factor 0.683 (2015)**.
13. „Secondary Acute Lymphoblastic Leukemia after Hodgkin's Lymphoma or a Coincidental Association of Two Hematological Malignancies?” - Tevet M, Dragan C, Saguna C, Barbu D, Lupu AR. Maedica (Buchar). 2013 Sep;8(4):370-6.
14. “Immunotherapy with Rituximab in Follicular Lymphomas” - Carmen SAGUNA, MD,a Ileana Delia MUT, MD, PhD, Anca Roxana LUPU, MD, PhD,a Mihaela TEVET, MD, SR,a Horia BUMBEA, MD, PhD,b and Cornel DRAGANA, Maedica 2011, 2011April; 6(2): 100-108.
15. “Acute myeloid leukemia in a 19 years old patient previously treated for osteosarcoma – case report and review of the literature” - Drăgan C., Meilin Murat, Trifa A., Tevet Mihaela. Therapeutics, Pharmacology and Clinical Toxicology. Vol XIX, Number 4, pg 165.
16. “Laparoscopic Splenectomy – Optimal Solution in Autoimmune Trombocytopenic Purpura” - B. Mastalier, W. Elaiah, Violeta Deaconescu, Irina Gal-Penciu, M. Leoveanu, Ioana Simion, C. Draghici, Mihaela Tevet, Sabina Zurac, C. Botezatu, International Multidisciplinary Research Journal, European Academic Research; **impact factor 0.5014 (2015)**.
17. “THE IMPORTANCE OF OXIDATIVE STRESS IN ABNORMALITIES OF PLATELET FUNCTION. THE RETROSPECTIVE STUDY IN CHRONIC MYELOID LEUKEMIA AND MYELODISPLASTIC SYNDROME PATIENTS” - Popov Viola, Minodora Iordache, Ana Maria Vladareanu, Mihaela Tevet, Thrombosis Research 141, SUPLM 1:89 May 2016; **impact factor 2.320 (2016)**.
18. „The analyses of efficacy and tolerability of Ruxolitinib in myelofibrosis patients - our experience” - Popov Viola, Anca Ilea, Meilin Murat, Mihaela Tevet, British Journal of Haematology 173(SUPPL 1):129 April 2016; **impact factor 5.401 (2016)**. **Quartile: Q1**
19. “THROMBOTIC COMPLICATIONS IN HEMATOLOGIC MALIGNANCIES” - M Popescu, D Georgescu, M Balea, M Tevet, O Patrinoiu, M Murat, HAEMATOLOGICA 101, 871-872; **impact factor 7.702 (2016)**.
20. „AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) ASSOCIATED TO NONHODGKIN'S LYMPHOMA (NHL)” Colita, A.; Lupu, A. R.; Angelescu, S.; Barbu, D.; Barca, G.; Closca, M.; Saguna, C.; Ciocan, O.; Ciobanu, A.; Ivanescu, A. M.; Oprea, M.; Popescu, D. Mut; Teleanu, V.; Negulescu, A.; Coriu, D.; Colita, A.,. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 93, pp. 1383-, 2008; **impact factor 3.487 (2008)**.
21. “FAVORABLE RESPONSE TO ALPHA-INTERFERON IN A PEDIATRIC PATIENT WITH AGNOGENIC MYELOIDMETAPLASIA COMBINED WITH FV LEIDEN ANOMALY”. HAEMATOLOGICA -THE HEMATOLOGY JOURNAL, 95, pp. 1521-2010, vol./is., Author(s): Colita A., Arion C., Lupu A., Puscaru T., Dobrea C., Closca M., Ciocan O., Diaconu C., Chivu M., Talmaci R., Coriu D., Avram S.
22. “Cytogenetic and molecular study of BCR/ABL negative chronic myeloproliferative disorders: preliminary data”. - M. E. Hinescu, A. Arghir, G. Cardos, C. Diaconu, M. Chivu, L. Dragomir, M. Closca, A. Lupu, D. Mut-Popescu, A. Lungeanu, publicat in Chromosome Research, vol. 15, nr. 1, p. 206; **impact factor 2.882 (2017)**.
23. „Antiemetic therapy in hematologic and nonhematologic malignancies” - Daniela, Georgescu G.; Mihaela, Popescu; Mihaela, Tevet; et al, Therapeutics Pharmacology and Clinical Toxicology. Volume XVIII Issue 3, September 2014.
24. „Assessment of prognostic factors in myelodysplastic syndromes” - Dana Georgescu, Mihaela Tevet et al. Therapeutics Pharmacology and Clinical Toxicology, vol XVIII. Issue 2, June 2014, page 72-77.
25. „Treatment with hypomethylating agents in myelodysplastic syndrome and acute myeloid leukemia. Therapeutics Pharmacology and Clinical Toxicology - Daniela Georgescu, Mihaela Tevet et all, vol XIX. Issue 2, June 2015.
26. „NEWS IN CYTOGENETIC AND MOLECULAR DIAGNOSIS TEL-JAK-2 FUSION AS A MODEL FOR HYBRID ONCOGENES” – Mihaela Closca-Gheorghiu, AR Lupu, Oana Ciocan, Anca Ciobanu, Aurora Arghir, Agripina Lungeanu - Maedica a Journal of Clinical Medicine vol 1 - nr. 3/2006 pg 46-53. **Quartile: Q1**
27. „COMPOSITE LYMPHOMAS - DIAGNOSIS AND EVOLUTION” - Mihaela Closca- Gheorghiu, AR. Lupu, O. Ciocan, A. Ciobanu, Cristina Mihai - Maedica a Journal of Clinical Medicine vol 1 - nr. 2/2006. **Quartile: Q1**
28. „NEW MOLECULAR MARKERS IN DIAGNOSIS OF SPLENIC LYMPHOMAS” - M. Closca- Gheorghiu, G. Ofiteru, A.R. Lupu, C. Saguna, O. Ciocan, A. Colita, A. Ciobanu, C. Mitrescu, E. Coles; Haematologica 2009; 94(s2); **impact factor 4.485 (2009)**.

29. „FOLLICULAR LYMPHOMA: INCIDENCE, PROGNOSTIC FACTORS AND OVERALL SURVIVAL IN 78 PATIENTS FOLLOWED FOR 7 YEARS(2002-2008) FROM A SINGLE INSTITUTION” - C. Saguna, M. Closca, O. Ciocan, A. Colita, A., Ciobanu, N. Berbec, R. Manolache, E. Coles, A.R. Lupu; Haematologica 2009, 94(s2); **impact factor 4.485 (2009)**.
30. „NEW MOLECULAR MARKERS IN DIAGNOSIS OF SPLENIC LYMPHOMAS” Autori: M. Closca-Gheorghiu, G. Ofiteru, A.R.Lupu, C. Saguna, O. Ciocan, A. Colita, A. Ciobanu, C. Mitrescu, E. Coles; Haematologica 2009; 94(s2); **impact factor 4.485 (2009)**.
31. „PRIMARY B-CELL CUTANEOUS LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE” - HAEMATOLOGICA- THE HEMATOLOGY JOURNAL, 94, pp. 1731-, 2009 - Colita, A.; Lupu, A. R.; Saguna, C.; Barca, G.; Ciocan, O.; Closca, M.; Ciobanu, A.; Ivanescu, A. M.; Oprea, M.; Angelescu, S.; Barbu, D. Coltea Hosp, Bucharest, Romania. [Dobrea, C.] Fundeni Clin Inst, Bucharest, Romania.
32. „AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) ASSOCIATED TO NON-HODGKIN'S LYMPHOMA (NHL)”. Autori: Colita,1 A.R. Lupu,1 S. Angelescu,1 D. Barbu2, G. Barca2, M. Closca2, Saguna,1 O. Ciocan,1 A. Ciobanu2, A.M. Ivanescu,1 M. Oprea2, D Mut Popescu2, V. Teleanu2, A. Negulescu2, D. Coriu,3 A. Colita3 Haematologica 2008; 93(s1); **impact factor 3.487 (2008)**.
33. „Apoptosis regulated protein levels and telomerase activity in high-grade non-Hodgkin's lymphomas” - C.D. Goia, M. Closca, A.R. Lupu, A. Ciobanu, O. Ciocan, M. Anton, G. Anton, 32nd FEBS Congress- Molecular Machines, 7- 12 iulie 2007, Viena, Austria, culegere de rezumate p. 177.
34. „New molecular markers in diagnosis of splenic lymphomas” - Autori: Anca-Roxana LUPU, MD, PhDa; Mihaela CLOSCA-GHEORGHIU, MD; Geanina Carla OFITERU, MDa; Elena COLES, MDa; Oana CIOCAN, MDa; Carmen SAGUNA, MDa; Anca CIOBANU, MDa; Ligia BARBARII, MD, Hematology Clinic, "Coltea" Clinical Hospital, Bucharest, Romania, Mædica A Journal of Clinical Medicine, Volume 4 No.1 2009 19. **Quartile: Q1**
35. „To horizon: The use of synthetic O blood group in practical substitutive therapy” - Autori: Anca Roxana LUPUa, MD, PhD, Anca CIOBANUb, MD, Oana CIOCANA, MD, Mihaela CLOSCA-GHEORGHIU, MD, Carmen SAGUNAA, MD, Irina CARAUSUc, MD "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, MÆDICA - a Journal of Clinical Medicine, Volume 2(5) No.2 2007. **Quartile: Q1**
36. „Determination of viral infections in malignant non-Hodgkin lymphomas” Autori: Cristina Daniela Goia1, Camelia Grancea1, Constanta Antipa1, Simona Ruta1, Camelia Sultana1, Anca Roxana Lupu2, Mihaela Closca2, Oana Ciocan2, 1Stefan S. Nicolau Institute of Virology 2Coltea Hospital - Hematology Clinic publicata in St. Cercet. Virusol. 37 (1) 2007; **impact factor 4.055 (2007)**.
37. „Cytogenetic and molecular study of BCR/ABL negative chronic myeloproliferative disorders: preliminary data” - M. E. Hinescu, A. Arghir, G. Cardos, C. Diaconu, M. Chivu, L. Dragomir, M.Closca, A. Lupu, D. Mut-Popescu, A. Lungeanu Rezumat publicat in Chromosome Research, vol. 15, nr. 1, p. 206; **impact factor 2.882 (2017)**.
38. „THE IMPORTANCE OF OXIDATIVE STRESS IN ABNORMALITIES OF PLATELET FUNCTION. THE RETROSPECTIVE STUDY IN CHRONIC MYELOID LEUKEMIA AND MYELODISPLASTIC SYNDROME PATIENTS” - Viola Popov, Minodora Iordache, Ana Maria Vladareanu, Horia Bumbea, Mihaela Georgeta Moiescu, Eugenia Kovacs, Tudor Savopol, Meilin Murat, Mihaela Tevet, Thrombosis Research 141 SUPLM 1:89 · May 2016; **impact factor 2.320 (2016)**.
39. Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence, Horia Bumbea, MD PhD, Ambroise Marçais, MD PhD, Daniel Coriu, MD PhD, Alina Daniela Tanase, MD PhD, Andrei Colita, MD PhD, Alexandru Bardas, MD, Anca Roxana Lupu, MD PhD, Ana-Maria Vladareanu, MD PhD, Minodora Cezarina Onisai, MD PhD, Viola Maria Popov, MD PhD MSc, Iuliana Iordan, MD, Magda Diana Cisleanu, MD PhD, Daniela Stefania Vasile, MD PhD, Cristina Maria Ciufu, MD PhD, Zsofia Varady, MD PhD, Oana Gabriela Craciun, MD, Daniela Georgeta Georgescu, MD PhD, Mihaela Andreescu, MD PhD, Cristina Mambet, MD, Carmen C. Diaconu, PhD, Laura Necula, PhD, Monica Bunaciu, Adriana Necula, Stefan N Constantinescu, MD PhD, Olivier Hermine, MD PhD, Blood (2019) 134 (Supplement_1): 5288; **impact factor 17.543 (2019)**.
40. EVALUATION OF THROMBOTIC RISK IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS, autori: Viola Popov, Mihaela Andreescu, Meilin Omer, Adrian Trifa, Oana Patrinoiu, Florina Raicu, Horia Bumbea – PB2311 AI 23-lea Congres anual al Societatii Europene de Hematologie, EHA 2018, 14-17 iunie 2018 Stockholm, Suedia publicate in HemaSphere 2(S1) – 2018.

41. Jan Jacques Michiels^{1*}, King H Lam², Fibo Ten Kate², Dong-Wook Kim³, Myungshin Kim⁴, Vasily Shuvaev⁵, Francisca Valster⁶, Vincent Potters⁷, Wilfried Schroyens⁸, Mihaela Andreescu⁹, Adrian Trifa¹⁰, Achille Pich¹¹ and Hendrik De Raeve¹² Novel European Asiatic Clinical, Laboratory, Molecular and Pathobiological (2015-2020 CLMP) criteria for JAK2V617F trilinear polycythemia vera (PV), JAK2exon12 PV and JAK2V617F, CALR and MPL515 thrombocythemias: From Dameshek to Constantinescu-Vainchenker, Kralovics and Michiels. *Int J Bone Marrow Res.* 2020; 3: 001-020.
42. The Importance of CD36 Expression in Evaluation of Thrombotic Risk in Patients with Myeloproliferative Neoplasms- Viola Popov, MD PhD MSc, Meilin Omer, MD, Adrian Trifa, MD PhD, ION Dumitru, MD, Oana Patrinoiu, MD PhD, Mihaela Andreescu, MD PhD, Horia Bumbea, MD PhD -*Blood* (2018) 132 (Supplement 1): 4989., <https://doi.org/10.1182/blood-2018-99-115349>; **impact factor 15.132 (2018)**.
43. CHARACTERISTICS OF DIAGNOSIS AND TREATMENT OUTCOME IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 60 YEARS-ANALYSES OF SINGLE CENTER: PB1760. - Popov, Viola; Georgescu, Daniela; Andreescu, M.; Arghir, Aurora; Dumitru, I.; Papuc, S.; Iova, A. ; Begu, M. ; Soare, Dan; Omer, M. ; Ofiteru, G. ; Patrinoiu, O. ; Mihai, F. ; Despan, Claudia ; Popescu, M. ; Balea, M. ; Gogulescu, R. ; Bumbea, Horia. (2019). *HemaSphere*. 3. 808- 809. 10.1097/ 01.H S9. 0000 565548. 51 0 0 5. fb.
44. Assessment of clinical evolution of COVID-19 and neoplastic malignancies patients - V Popov, M Andreescu, M Popescu, O Patrinoiu, L Iliescu, B Mastalier, et all - *AMERICAN JOURNAL OF HEMATOLOGY* 95, S26-S27; **impact factor 10.047 (2020)**. **Quartile: Q1**
45. CLL-370: The Prolonged Positivity of SARS-CoV-2 RNA in Chronic Lymphocytic Leukemia Patients - V Popov, M Andreescu, O Patrinoiu, M Popescu, C Despan, M Omer, et all *Clinical Lymphoma Myeloma and Leukemia* 20, S228; **impact factor 2.36 (2020)**.
46. PB1760 CHARACTERISTICS OF DIAGNOSIS AND TREATMENT OUTCOME IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 60 YEARS-ANALYSES OF SINGLE CENTER - V Popov, D Georgescu, M Andreescu, A Arghir, I Dumitru, SM Papuc, et all - *HemaSphere* 3 (S1), 808-809.
47. Assessment of Changes of Membrane Properties and Platelets Function in Patients with Chronic Myeloid Leukaemia- Viola Popov, Vladareanu ANA Maria, Matei MIRCEA Bogdan, Matei Christien Oktaviani, Mihaela Georgeta Moisescu, Kovacs Eugenia, Meilin Omer, Mihaela Andreescu, Oana Patrinoiu, Savopol Tudor, Horia Bumbea - *Blood* 130 (Supplement 1), 4846-4846; **impact factor 13.164 (2017)**.
48. THE IMPORTANCE OF PLATELET MEMBRANE FLUIDITY AND OXIDATIVE STRESS IN THROMBOTIC COMPLICATIONS ACQUIRED BY CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS - VM Popov, M Andreescu, M Omer, A Trifa, F Mihai, C Dragan, O Patrinoiu, et all - *HAEMATOLOGICA* 102, 649-650; **impact factor 9.090 (2017)**.
49. Hypereosinophilic syndromes FIP1L1/PDGFR fusion gene NEGATIVE-hematological remission on imatinib mesilate: 522 - D Georgescu, O Patrinoiu, V Popov, M Tevet, M Balea, S Zurac, C Dobrea, *British Journal of Haematology* 173, 175-176; **impact factor 5.401 (2016)**. **Quartile: Q1**
50. The analyses of efficacy and tolerability of ruxolitinib in myelofibrosis patients-our experience - VM Popov, M Tevet, M Murat, CV Dragan, DG Georgescu, OFG Patrinoiu, et all - *BRITISH JOURNAL OF HAEMATOLOGY* 173, 129-129; **impact factor 5.401 (2016)**. **Quartile: Q1**

● POSTERE

Postere la conferinte Internationale si Nationale:

1. The Prolonged Positivity of SARSCoV-2 RNA in Chronic Lymphocytic Leukemia Patients-Viola Popov*, Mihaela Andreescu, Oana Patrinoiu, Mihaela Popescu, Claudia Despan, Meilin Omer, Felicia Mihai, Geanina Ofi teru, Marius Lucian Balea, Silvia Ion, Daniela Georgescu - Hematology Department, Colentina Clinical Hospital, Bucharest, Romania- Clinical Lymphoma, Myeloma & Leukemia September 2020, pagina S228; **impact factor 2.36 (2020)**.
2. „A case of acute lymphoblastic leukemia associated with acute pancreatitis at onset” - Felicia Mihai, Cornel Dragan, Meilin Murat, Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Marius Balea, Mihaela Tevet. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
3. „The influence of oxidative stress on the platelet membrane among the patient with CGL”. - Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
4. „Alterations of platelet membrane functions among the patients with chronic myeloproliferative neoplasms” - Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
5. „The treatment with 5 AZACITIDINE in MDS and AML – practical aspects from the clinical experience of Colentina Clinical Hospital” - Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Viola Popov, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
6. „Evolution under treatment with tirosine kinase inhibitors in one case of chronic myeloid leukemia, blastic phase at onset”. - Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Viola Popov, Daniela Georgescu, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
7. „Case presentation: prognostic factors, classification, and risk models for overall survival prediction in MDS patients” - Mihaela Tevet et al. Poster Abstract - SRH 2013. DOCUMENTA HAEMATOLOGICA Vol. XX, Nr. 1-2, 2013.
8. „Postsplenectomy evolution in one case of hypoplastic myelodysplastic syndrome”. Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - the 12th International Symposium on Myelodysplastic Syndromes, Berlin, Germany, May 8-11, 2013.
9. „Evolution under treatment with VIDAZA in one case of RAEB-2”. - Dana Georgescu, Mihaela Tevet et al. Poster Abstract - cea de-a 4-a Conferinta Internationala a SMD, Estoril, Portugalia, 15- 17.05.2014.
10. „The treatment with hypomethylating agents in hematology” - Daniela Georgescu, Mihaela Tevet et al.- Poster Abstract - Congres AMR 2015. Romania Medical Magazine - Volumul LXII, Supplement 1, 2015.
11. „The experience of a single center of hematology in the treatment with hypomethylating agents.” - Daniela Georgescu, Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - Cel de-al 13-lea Simpozion in SMD Washington, USA, aprilie/mai 2015.
12. „The experience of one romanian center of hematology in the treatment with hypomethylating agents” - Daniela Georgescu, Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - The 5 International Congres Lymphoma Myeloma, Istanbul, Turcia, 21-23 May 2015.
13. „Second malignant tumors associated with hematological malignancies - frequency and significance” - Balea Marius Lucian, Dana Georgescu, Mihaela Tevet et al, Poster Abstract - EHA 2014. Abstract PB1731; ABSSUB - 5209.
14. „The implication of hepatitis c virus in B-cells limphoproliferative disorders – A.Lupu, M. Closca-Gheorghiu, O.Ciocan, C.Alexa, S.Avram, S.Angelescu, A.Colita, H.Bumbea, N.Olteanu, D.Popescu- Mut. ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 3- SUPPLEMENT 1 JUNE 2002- THE 7TH ANNUAL MEETING OF THE EUROPEAN HEMATOLOGY ASSOCIATION FLORENCE, ITALY, 6-9 JUNE, 2002.
15. „T- cell ALL - Retrospective Study” - A.R.Lupu, Oana Ciocan, C.Alexa, M. Closca Gheorghiu, N.Berbec, S.Avram, H. Bumbea, D.Cisleanu, A.Colita, D.Barbu, D.Mut- Popescu - ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 4- SUPPLEMENT 2 JUNE 2003- THE 8TH ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION-LYON, FRANCE, 12- 15 JUNE, 2003.
16. „Tuberculosis infection in acute leukemia – a report of 5 cases” - A.R.Lupu, Oana Ciocan, M. Closca Gheorghiu,

C.Alexa, N.Berbec, H.Bumbea, A.Colita, S.Angelescu, V.Gaman, D.Mut- Popescu ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 4 - SUPPLEMENT 2 JUNE 2003- THE 8TH ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION- LYON, FRANCE, 12-15 JUNE, 2003.

17. „Recurrent and rare chromosomal abnormalities in acute leukemias – a 5 years study” (poster EP12.001) - Papuc S, Tutulan-Cunita A, Cristea M, Borcan I, Bumbea H, Cisleanu D, Tevet M, Popov V, Dragan C, Berbec N, Angelescu S, Vladareanu AM, Arghir A, ESHG Conference, Barcelona, 2016, resume published in EJHG 24E- S1:457; **impact factor 4.287 (2016)**.
18. „Study on Membrane Fluidity and medication influences in Chronic Myeloid Leukemia and Myeloproliferative Neoplasms” - Viola Maria Popov¹, Maria Minodora Iordache², Mihaela Tevet¹, Eugenia Kovacs², Tudor Savopol², Mihaela Georgeta Moisescu², Daniela Georgescu¹, Meilin Murat¹, Cornel Dragan¹, Mihaela Popescu¹, Conferinta Nationala Biofizica Timisoara 2015 poster.
19. „The influence of oxidative stress on the platelet membrane among the patient with CGL”. - Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
20. „Alterations of platelet membrane functions among the patients with chronic myeloproliferative neoplasms” - Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
21. „The treatment with 5 AZACITIDINE in MDS and AML – practical aspects from the clinical experience of Colentina Clinical Hospital” - Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Viola Popov, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
22. „Evolution under treatment with tyrosine kinase inhibitors in one case of chronic myeloid leukemia, blastic phase at onset”. - Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Viola Popov, Daniela Georgescu, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
23. „Case presentation: prognostic factors, classification, and risk models for overall survival prediction in MDS patients” - Mihaela Tevet et al. Poster Abstract - SRH 2013. DOCUMENTA HAEMATOLOGICA Vol. XX, Nr. 1-2, 2013.
24. „Postsplenectomy evolution in one case of hypoplastic myelodysplastic syndrome”. Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - the 12th International Symposium on Myelodysplastic Syndromes, Berlin, Germany, May 8-11, 2013.
25. „Evolution under treatment with VIDAZA in one case of RAEB-2”. - Dana Georgescu, Mihaela Tevet et al. Poster Abstract - cea de-a 4-a Conferinta Internationala a SMD, Estoril, Portugalia, 15- 17.05.2014.
26. „The treatment with hypomethylating agents in hematology” - Daniela Georgescu, Mihaela Tevet et al.- Poster Abstract - Congres AMR 2015. Romania Medical Magazine - Volumul LXII, Supplement 1, 2015.
27. „The experience of a single center of hematology in the treatment with hypomethylating agents.” - Daniela Georgescu, Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - Cel de-al 13-lea Simpozion in SMD Washington, USA, aprilie/mai 2015.
28. „The experience of one romanian center of hematology in the treatment with hypomethylating agents” - Daniela Georgescu, Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - The 5 International Congres Lymphoma Myeloma, Istanbul, Turcia, 21-23 May 2015.
29. „Second malignant tumors associated with hematological malignancies - frequency and significance” - Balea Marius Lucian, Dana Georgescu, Mihaela Tevet et al, Poster Abstract - EHA 2014. Abstract PB1731; ABSSUB - 5209.
30. „The implication of hepatitis c virus in B-cells limphoproliferative disorders – A.Lupu, M. Closca-Gheorghiu, O.Ciocan, C.Alexa, S.Avram, S.Angelescu, A.Colita, H.Bumbea, N.Olteanu, D.Popescu- Mut. ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 3- SUPPLEMENT 1 JUNE 2002- THE 7TH ANNUAL MEETING OF THE EUROPEAN HEMATOLOGY ASSOCIATION FLORENCE, ITALY, 6-9 JUNE, 2002.
31. „T- cell ALL - Retrospective Study” - A.R.Lupu, Oana Ciocan, C.Alexa, M. Closca Gheorghiu, N.Berbec, S.Avram, H. Bumbea, D.Cisleanu, A.Colita, D.Barbu, D.Mut- Popescu - ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 4- SUPPLEMENT 2 JUNE 2003- THE 8TH ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION-LYON, FRANCE, 12- 15 JUNE, 2003.
32. „Tuberculosis infection in acute leukemia – a report of 5 cases” - A.R.Lupu, Oana Ciocan, M. Closca Gheorghiu, C.Alexa, N.Berbec, H.Bumbea, A.Colita, S.Angelescu, V.Gaman, D.Mut- Popescu ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 4 - SUPPLEMENT 2 JUNE 2003- THE 8TH ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION- LYON, FRANCE, 12-15 JUNE, 2003.

33. „Recurrent and rare chromosomal abnormalities in acute leukemias – a 5 years study” (poster EP12.001) - Papuc S, Tutulan-Cunita A, Cristea M, Borcan I, Bumbea H, Cisleanu D, Tevet M, Popov V, Dragan C, Berbec N, Angelescu S, Vladareanu AM, Arghir A, ESHG Conference, Barcelona, 2016, resume published in EJHG 24E- S1:457; **impact factor 4.287 (2016)**.
34. „Study on Membrane Fluidity and medication influences in Chronic Myeloid Leukemia and Myeloproliferative Neoplasms” - Viola Maria Popov¹, Maria Minodora Iordache², Mihaela Tevet¹, Eugenia Kovacs², Tudor Savopol², Mihaela Georgeta Moiescu², Daniela Georgescu¹, Meilin Murat¹, Cornel Dragan¹, Mihaela Popescu¹, Conferinta Nationala Biofizica Timisoara 2015; poster.
35. „The influence of oxidative stress on the platelet membrane among the patient with CGL”. - Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
36. „Alterations of platelet membrane functions among the patients with chronic myeloproliferative neoplasms” - Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
37. „The treatment with 5 AZACITIDINE in MDS and AML – practical aspects from the clinical experience of Colentina Clinical Hospital” - Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Viola Popov, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
38. „Evolution under treatment with tirosine kinase inhibitors in one case of chronic myeloid leukemia, blastic phase at onset”. - Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Viola Popov, Daniela Georgescu, Marius Balea, Meilin Murat, Cornel Dragan. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
39. „Case presentation: prognostic factors, classification, and risk models for overall survival prediction in MDS patients” - Mihaela Tevet et al. Poster Abstract - SRH 2013. DOCUMENTA HAEMATOLOGICA Vol. XX, Nr. 1-2, 2013.
40. „Postsplenectomy evolution in one case of hypoplastic myelodysplastic syndrome”. Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - the 12th International Symposium on Myelodysplastic Syndromes, Berlin, Germany, May 8-11, 2013.
41. „Evolution under treatment with VIDAZA in one case of RAEB-2”. - Dana Georgescu, Mihaela Tevet et al. Poster Abstract - cea de-a 4-a Conferinta Internationala a SMD, Estoril, Portugalia, 15- 17.05.2014.
42. „The treatment with hypomethylating agents in hematology” - Daniela Georgescu, Mihaela Tevet et al.- Poster Abstract - Congres AMR 2015. Romania Medical Magazine - Volumul LXII, Supplement 1, 2015.
43. „The experience of a single center of hematology in the treatment with hypomethylating agents.” - Daniela Georgescu, Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - Cel de-al 13-lea Simpozion in SMD Washington, USA, aprilie/mai 2015.
44. „The experience of one romanian center of hematology in the treatment with hypomethylating agents” - Daniela Georgescu, Mihaela Tevet et al. POSTER PRESENTATION ABSTRACT - The 5 International Congres Lymphoma Myeloma, Istanbul, Turcia, 21-23 May 2015.
45. „Second malignant tumors associated with hematological malignancies - frequency and significance” - Balea Marius Lucian, Dana Georgescu, Mihaela Tevet et al, Poster Abstract - EHA 2014. Abstract PB1731; ABSSUB - 5209.
46. „The implication of hepatitis c virus in B-cells limphoproliferative disorders – A.Lupu, M. Closca-Gheorghiu, O.Ciocan, C.Alexa, S.Avrarn, S.Angelescu, A.Colita, H.Bumbea, N.Olteanu, D.Popescu- Mut. ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 3- SUPPLEMENT 1 JUNE 2002- THE 7TH ANNUAL MEETING OF THE EUROPEAN HEMATOLOGY ASSOCIATION FLORENCE, ITALY, 6-9 JUNE, 2002.
47. „T- cell ALL - Retrospective Study” - A.R.Lupu, Oana Ciocan, C.Alexa, M. Closca Gheorghiu, N.Berbec, S.Avrarn, H. Bumbea, D.Cisleanu, A.Colita, D.Barbu, D.Mut- Popescu - ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 4- SUPPLEMENT 2 JUNE 2003- THE 8TH ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION-LYON, FRANCE, 12- 15 JUNE, 2003.
48. „Tuberculosis infection in acute leukemia – a report of 5 cases” - A.R.Lupu, Oana Ciocan, M. Closca Gheorghiu, C.Alexa, N.Berbec, H.Bumbea, A.Colita, S.Angelescu, V.Gaman, D.Mut- Popescu ABSTRACT publicat in THE HEMATOLOGY JOURNAL, VOLUME 4 - SUPPLEMENT 2 JUNE 2003- THE 8TH ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION- LYON, FRANCE, 12-15 JUNE, 2003.
49. „Recurrent and rare chromosomal abnormalities in acute leukemias– a 5 years study” (poster EP12.001)- Papuc S, Tutulan-Cunita A, Cristea M, Borcan I, Bumbea H, Cisleanu D, Tevet M, Popov V, Dragan C, Berbec N, Angelescu S, Vladareanu AM, Arghir A, ESHG Conference, Barcelona, 2016, resume published in EJHG 24E- S1:457.
50. „Study on Membrane Fluidity and medication influences in Chronic Myeloid Leukemia and Myeloproliferative Neoplasms” - Viola Maria Popov¹, Maria Minodora Iordache², Mihaela Tevet¹, Eugenia Kovacs², Tudor Savopol²,

Mihaela Georgeta Moisescu², Daniela Georgescu¹, Meilin Murat¹, Cornel Dragan¹, Mihaela Popescu¹, Conferinta Nationala Biofizica Timisoara 2015; poster.

51. „Is membrane fluidity an important parameter in platelet function” - Viola Maria Popov¹, Ana Maria Vladareanu², Horia Bumbea², Mihaela Tevet¹, Eugenia Kovacs³, Tudor Savopol³, Conferinta Internationala a ISLH Chicago 2015, IJLH, John Wiley & Sons Ltd, Int. Jnl. Lab. Hem. 2015 37 (Suppl.2) 114 poster; **impact factor 2.401 (2015)**.
52. „The analyses of efficacy and tolerability of ruxolitinib in myelofibrosis patients-our experience” - VM Popov, M Tevet, M Murat, CV Dragan, DG Georgescu, OFG Patrinoiu, poster, Conferinta internationala a ISH Glasgow 2016, publicat in BRITISH JOURNAL OF HAEMATOLOGY 173, 129- 129; **impact factor 5.401 (2016)**.
53. „The importance of oxidative stress in abnormalities of platelet function. The retrospective study in chronic myeloid leukemia and myelodysplastic syndrome patients” - VM Popov, MM Iordache, E Kovacs, MG Moisescu, M Tevet, Conferinta Internationala DLTH 2016 Istanbul 2016, publicata in THROMBOSIS RESEARCH 141, S81-S81 poster; **impact factor 2.320 (2016)**.
54. „The role of JAK2 and CALR/MPL mutations in clinical evolution of patients with chronic myeloproliferative neoplasms - the experience of one hematological center” - Viola Maria Popov¹, Mihaela Tevet¹, Felicia Mihai¹ Meilin Murat¹, Cornel Dragan¹, Daniela Georgescu¹, Mihaela Popescu¹, Marius Balea¹, Oana Patrinoiu¹ Adrian Trifa², ESH Conference for Myeloproliferative Neoplasms, Estoril 2016 poster.
55. „The frequency and pathogeny of renal disease in malignant hemopathies” - Dr. Marius Lucian Balea, Dr. Tevet Mihaela, Dr. Daniela Georgescu, Dr. Mihaela Popescu, Dr. Viola Popov Maria, Dr. Oana Patrinoiu, Dr. Murat Meilin. National Conference of Clinical and Transfusional Hematology, Sinaia 2014. Poster.
56. „Structural anomalies of chromosome 11 in myeloid and lymphoid malignancies” (poster) - Arghir A, Papuc SM, Bumbea H, Cisleanu D, Tevet M, Popov V, Vladareanu AM, Tutulan-Cunita A - Simpozionul N. Cajal al ASM, 17-19.03.2016, Bucuresti; rezumat publicat in volumul simpozionului.
57. „Concentration TNF (Tumour Necrosis Factor) alfa variation's significance in Essential Thrombocythaemia (ET), JAK2(V617F)+ and JAK2(V617F)-, in ANAGRELIDE therapy; Preliminary data” - Dr. Marius Balea(1), Dr Anca Ilea(2), Dr Oana Patrinoiu (1), Dr Mihaela Popescu (1), Dr Dana Georgescu (1) , Dr. Melin Murat (1), Dr. Cornel Dragan(1), Dr. Mihaela Tevet(1), Dr. Viola Popov(1). National Conference of Clinical and Transfusional Hematology, Sinaia 2015 poster.
58. „The result of molecular analysis to detect bcr-abl hybrid gene in lingual epithelium cells in subjects with ph chromosome positive / bcr-abl positive CML” - Dr. Marius. Balea(1), Dr Anca Ilea(2), Dr Oana Patrinoiu (1), Dr Mihaela Popescu (1), Dr Dana Georgescu (1) , Dr. Melin Murat (1), Dr. Cornel Dragan(1), Dr. Mihaela Tevet(1), Dr. Viola Popov(1). National Conference of Clinical and Transfusional Hematology, Sinaia 2015 poster.
59. „Acute Myeloid Leukemia after Osteosarcoma in a 19 year old patient” - Cornel Dragan, Meilin Murat, Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Marius Balea, Mihaela Tevet. National Conference of Clinical and Transfusional Hematology, Sinaia 2015. Poster.
60. „Cytogenetic and molecular study of BCR/ABL negative chronic myeloproliferative disorders: preliminary data”. - M. E. Hinescu, A. Arghir, G. Cardos, C. Diaconu, M. Chivu, L. Dragomir, M. Closca, A. Lupu, D. Mut-Popescu, A. Lungeanu, poster prezentat la a 6-A CONFERINTA EUROPEANA DE CITOGENETICA, ISTANBUL 7-10.07.2007.
61. „Evolution of patients with essential thrombocytemia (ET) treated with Hydroxyurea (HU) and alpha - interferon (IFN)” - A. Colita, AR. Lupu, N Berbec, G Mocanu, S Angelescu, D. Barbu, C. Vlaicu, S. Crintea, O. Ciocan, M. Closca, AM Vladareanu, H Bumbea, DM Popescu, poster prezentat la 11th Congress of the European Hematology Association, Amsterdam, Netherlands, 15 -18 June 2006.
62. „T-CELL ALL - RETROSPECTIV STUDY” - A. Lupu, O. Ciocan, C. Alexa, M. Closca-Gheorghiu, N. Berbec, S. Avram, D. Cisleanu, A. Colita, D. Barbu, D.M. Popescu Rezumat publicat in "The Hematology Journal", vol4 supl12, June 2003 poster prezentat la 8TH Annual Congress of the European Hematology Association, Lyon, France, 2003.
63. „PROGNOSIS FACTORS IN MYELOYDYSPLASTIC SYNDROMES” - A. Lupu, M. Closca Department of Hematology, Coltea Hospital Rezumat publicat in "The Hematology Journal", vol3 supl11, June 2002, poster prezentat la 7TH MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION JUNE 2002, FLORENCE, ITALY.
64. „Multiple Myeloma in young patients - clinical aspects, evolution and treatment chalanges”. - Meilin Murat, Cornel Dragan, Viola Popov, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Mihaela Tevet, Marius Balea. National Conference of Clinical and Transfusional Hematology, Sinaia 2015; poster.
65. „The evaluation of oxidative status and platelet membrane function in chronic myeloproliferative neoplasms patients” - la XXXIst International Symposium on Technological Innovations in Laboratory Hematology, 10-12 mai 2018, Bruxelles, Belgia, autori: V Popov, C.O Matei, B.M. Matei, I. Dumitru, M. Omer, M.G. Moisescu, T. Savopol, O

Patrinoiu, M. Andreescu, F. Mihai, A.M. Vladareanu, H. Bumbea, Poster No 290.

66. „BIOLOGICAL IMMUNOPHENOTYPIC AND THERAPEUTICAL ASPECTS IN LYMPHOPLASMACYTOID LYMPHOMAS” - A.Lupu, C Alexa, M.Closca, O.Ciocan, H.Bumbea, N.Olteanu, A.Colita, S. Avram, S. Angelescu, D.Popescu - Department of Hematology , Coltea Hospital"- Rezumat publicat in "The Hematology Journal", vol 1 - iunie 2001, poster prezentat la 6th MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION 21-24 JUNE 2001, Messe Congress Center FRANKFURT, GERMANY.
67. „THE ROLE OF REACTIVE SPECIES PRODUCTION IN ASSESSMENT OF THROMBOTIC RISK IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS” - la 25th Biennial International Congress on Thrombosis, Venetia, Italia, 23-26 mai 2018, autori: V Popov, MG Moiescu, T Savopol, CO Matei, BM Matei, M Omer, F. Mihai, O Patrinoiu, M Andreescu, I. Dumitru, AM Vladareanu, H Bumbea, Poster P-0159.
- 68.„The fluidity of platelet membrane an important parameter for platelet function in chronic myeloproliferative neoplasms patients” - la 64th Meeting of the International Society on Thrombosis and Haemostasis, Dublin, Irlanda, 18-21 iulie 2018, autori: Viola Maria Popov, Horia Bumbea, Tudor Savopol, Ion Dumitru, Bogdan Matei, Christien Oktaviani Matei, Mihaela Andreescu, Meilin Omer, Felicia Mihai, Oana Patrinoiu, Ana Maria Vladareanu, Mihaela Georgeta Moiescu, Poster PB041; Pentru acest poster Popov Viola Maria a primit premiul Reach the World Grant.
- 69.„Diagnostic difficulties in acute leukemias” - Mihaela Tevet, Dana Georgescu et al. Poster Abstract - SRH 2013. DOCUMENTA HAEMATOLOGICA Vol. XX , Nr. 1-2, 2013.
- 70.„Multiple Myeloma in young patients - Clinical specifications, evolution and treatment options” - Meilin Murat, Cornel Dragan, Mihaela Tevet, Viola Popov, Mihaela Popescu, Felicia Mihai, Marius Balea, Daniela Georgescu et al. Poster Abstract - SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
71. CHROMOSOME 11 ANOMALIES IN ACUTE LEUKEMIAS Aurora Arghir^{1,2}, Sorina Mihaela Papuc¹ , Diana Cişleanu^{2,3}, Viola Popov⁴ , Ion Dumitru³ , Raluca Colesniuc¹ , Dan Soare^{2,3}, Cristina Enache³ , Mihaela Andreescu⁴ , Ana-Maria Vlădăreanu^{2,3}, Horia Bumbea^{2,3}, 2nd National Congress of the Romanian Association of Laboratory Medicine with International Participation, Revista Română de Medicină de Laborator Supliment la Vol. 26, Nr. 2, Aprilie, 2018, poster presentation; **impact factor 0.800 (2018)**.
72. STRUCTURAL ANOMALIES OF CHROMOSOME 11 IN MYELOID AND LYMPHOID MALIGNANCIES A. Arghir¹ , S.M. Papuc¹ , H. Bumbea² , D. Cisleanu² , M. Tevet³ , V. Popov³ , A.M. Vladareanu² , A. Tutulan-Cunita¹, poster presentation Conferinta Nationala Genetica 2016, Journal of Translational Medicine and Research 21 (Supplement I), 2016, S49; **impact factor 3.786 (2016)**.
73. MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA WITH NORMAL CYTOGENETICS IN ROMANIAN PATIENTS - A TARGETED NEXT GENERATION SEQUENCING PRELIMINARY REPORT, Aurora Arghir, Sorina Mihaela Papuc, Dan-Sebastian Soare, Eugen Radu, Iuliana Ciocănea-Teodorescu, Viola Popov, Mihaela Găman, Cristina Marinescu, Anca Nicolescu, Raluca Colesniuc, Meilin Murat, Mihaela Popescu, Oana Patrinoiu, Mihaela Andreescu, Nicoleta Berbec, Silvana Angelescu, Diana Cişleanu, Ana-Maria Vlădăreanu, Horia Bumbea EHA Library. Arghir A. 06/14/18; 216210; PB1712 poster presentation.
74. Assessment of Hematologic and Coagulation Parameters As Predictive Value in COVID-19 with Unfavourable Evolution, Viola Maria Popov, MD PhD MSc, Lelia Iliescu, MDPHd, Marius Ioan Balea, MD, Daniela Georgeta Georgescu, MDPHd, Mihaela Andreescu, MDPHd, Horia Bumbea, MD PhD, Meilin Omer, MD, Marius Lucian Aurel Balea, MDPHd, Catalina Parvu, MD, Andra Bogdana Grigorie, MD, Mihaela Popescu, MD, Oana Patrinoiu, MDPHd, Ana Rus, MD, Daniela Gologanu, MD, Valentin Nedelcu, MD, Geanina Ofiteru, MD, Claudia Despan, MD, Mihaela Niculae Badoiu, MD, Adriana Badea, MD, Oana Constantin, MD, Lidia Felicia Mihai, MD, Andreea Calen, MD, Silvia Ion, MD, Gabriel Adrian Popescu, MDPHd, Adriana Hristea, MDPHd, Bogdan Mastalier, MDPHd, Bogdan Diaconescu, MDPHd, Blood (2020) 136 (Supplement 1): 13., poster presentation ASH 2020; **impact factor 22.113 (2020)**.
75. Assessment of clinical evolution of COVID-19 and neoplastic malignancies patients, Viola Popov¹, Mihaela Andreescu¹, Mihaela Popescu¹, Oana Patrinoiu¹, Lelia Iliescu¹, Bogdan Mastalier¹, Horia Bumbea², Marius Lucian Aurel Balea¹, Meilin Omer¹, Geanina Ofiteru¹, Felicia Mihai¹, Claudia Despan¹, Silvia Ion¹, Adriana Hristea³, Gabriel Popescu³, Daniela Georgescu¹, poster presentation, AJH, Volume 95, Issue S1 Supplement: Abstracts from the 2020 Lymphoma, Leukemia and Myeloma Congress October 21-24, 2020; **impact factor 10.047 (2020)**.
76. The Evaluation of Haematological and Biochemistry Parameters in COVID-19 Patients as a Predictive Factor for Unfavourable Evolution, Viola Popov ^{1*}, Lelia Iliescu ², Marius Ioan Balea ³, Mihaela Andreescu ¹, Mihaela Popescu ¹, Oana Patrinoiu ¹, Geanina Ofiteru ¹, Claudia Despan ¹, Meilin Omer ¹, Silvia Ion ¹, Marius Lucian Aurel Balea ¹, Catalina Parvu ², Oana Constantin ², Jeanina Valcea ², Adriana Badea ², Ana Rus ², Mihaela Niculae ², Andreea Calen ², Andra Grigorie ², Valentin Nedelcu ³, Daniela Gologanu ³, Daniela Georgescu, Clinical Lymphoma, Myeloma & Leukemia, 2020, Vol 20 , poster presentation at SOHO 2020.
77. The Assessment of Platelet Membrane Alteration in Patients with Chronic Myeloproliferative Neoplasms, V. Popov¹, C.O. Matei², M. Andreescu³, M.G. Moiescu², T. Savopol, Res Pract Thromb Haemost. 2020; 4 (Suppl 1), poster presentation;

78. The evaluation of oxidative status and platelet membrane function in chronic myeloproliferative neoplasms patients V Popov, C.O Matei, B.M. Matei, I. Dumitru, M. Omer, M.G. Moisesescu, T. Savopol, O Patrinoiu, M. Andreescu, F. Mihai, A.M. Vladareanu, H. Bumbea, Prezentare poster: la XXXIst International Symposium on Technological Innovations in Laboratory Hematology, 10-12 mai 2018, Bruxelles, Belgia, PosterNo290, http://www.islh.org/2018/program.php?page=program&displayday=2&pads=&start_range=&start_interval=&changing_days=yes&hide_details=.
79. The Importance of CD36 Expression in Evaluation of Thrombotic Risk in Patients with Myeloproliferative Neoplasms, Viola Popov, MD PhD MSc, Meilin Omer, MD, Adrian Trifa, MD PhD, ION Dumitru, MD, Oana Patrinoiu, MD PhD, Mihaela Andreescu, MD PhD, Horia Bumbea, MD PhD, Blood (2018) 132 (Supplement 1): 4989; **impact factor 15.132 (2018)**.
80. The Importance of Fluorescence Anisotropy of Platelet Membrane in Platelet Receptor Expression in Chronic Patients with Chronic Myeloproliferative Neoplasms V Popov, H. Bumbea, T.Savopol, I. Dumitru, B.M.Matei, C.O Matei, M. Andreescu, M. Omer, F. Mihai, O Patrinoiu, A.M.Vladareanu, M.G. Moisesescu Prezentare poster: la ESH International Conference on MPN, Saagart-Dublin, Irlanda, 15-17 mai 2018.
81. THE ROLE OF REACTIVE SPECIES PRODUCTION IN ASSESSMENT OF THROMBOTIC RISK IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS V Popov, MG Moisesescu, T Savopol, CO Matei, BM Matei, M Omer, F. Mihai, O Patrinoiu, M Andreescu, I. Dumitru, AM Vladareanu, H Bumbea, Prezentare poster: la 25th Biennial International Congress on Thrombosis, Venetia, Italia, 23-26 mai 2018, Poster P-0159, http://www.thrombosis2018.org/index.php?go=pre_comunicacion.
82. The fluidity of platelet membrane an important parameter for platelet function in chronic myeloproliferative neoplasms patients Viola Maria Popov, Horia Bumbea, Tudor Savopol, Ion Dumitru, Bogdan Matei, Christien Oktaviani Matei, Mihaela Andreescu, Meilin Omer, Felicia Mihai, Oana Patrinoiu, Ana Maria Vladareanu, Mihaela Georgeta Moiesc, Poster PB041, Prezentare poster: la 64th Meeting of the International Society on Thrombosis and Haemostasis, Dublin, Irlanda, 18-21 iulie 2018, premiul Reach the World Grant.
83. The assessment of JAK 2 mutation role in platelet membrane fluidity changes in chronic myeloproliferative neoplasms patients VM Popov, CO Matei, B Matei, A. Trifa, F. Raicu, M. Omer, R. Leu, T. Savopol, MG Moisesescu, E Kovacs, M Andreescu, AM Vladareanu, H. Bumbea Prezentare poster: la XXXVII World Congress of the International Society of Hematology (ISH 2018), 13-16 septembrie 2018, Vancouver, Canada.
84. The analyses of thrombotic risk in chronic myeloproliferative neoplasms patients, V.M. Popov, A. Trifa, M. Omer, M. Andreescu, F. Mihai, F. Raicu, S. Chioveanu, A. M. Grigoriu 10th International Congress on Myeloproliferative Neoplasms and Chronic Myeloid Leukemia, 2-3 noiembrie 2017, New York 2017, Poster, P104.
85. Evaluation of Platelet Membrane Fluidity in Assessment of Thrombosis Risk at Chronic Myeloproliferative Neoplasms Patients, V. M. Popov, M. B. Matei, C. O. Matei, M. G. Moisesescu, M. Omer, M. Andreescu, F. Mihai, E. Kovacs, A. M. Vladareanu, H. Bumbea, T. Savopol, 10th International Congress on Myeloproliferative Neoplasms and Chronic Myeloid Leukemia, 2-3 noiembrie 2017, New York 2017, Poster, P105.
86. The importance of platelet membrane fluidity and oxidative stress in thrombotic complications acquired by chronic myeloproliferative neoplasm patients ,V. M. Popov, M. Andreescu, M. Omer, A. Trifa, F. Mihai, C. Dragan, O. Patrinoiu, M. G. Moisesescu, T. Savopol, E. Kovacs, H. Bumbea, A. M. Vladareanu , European Hematology Congress Madrid 22-25 iunie 2017 E Poster, E1602 Hematologica, June 2017, 102:1-882, p 663.
87. The importance of platelet membrane fluidity and oxidative stress in thrombotic complications acquired by chronic myeloproliferative neoplasm patients, V. M. Popov, M. Andreescu, M. Omer, A. Trifa, F. Mihai, C. Dragan, O. Patrinoiu, M. G. Moisesescu, T. Savopol, E. Kovacs, H. Bumbea, A. M. Vladareanu, 22th EHA Congress, 22-25 iunie 2017, Madrid, Spania, Eposter, E1602 Hematologica, June 2017, 102:1-882, p 663.
88. Evaluation of Platelet Membrane Fluidity in Assessment of Thrombosis Risk at Chronic Myeloproliferative Neoplasms Patients, V. M. Popov, M. B. Matei, C. O. Matei, M. G. Moisesescu, M. Omer, M. Andreescu, F. Mihai, E. Kovacs, A. M. Vladareanu, H. Bumbea, T. Savopol, 10th International Congress on Myeloproliferative Neoplasms and Chronic Myeloid Leukemia, 2-3 noiembrie 2017, New York 2017 Poster, P105.
89. Assessment of Changes of Membrane Properties and Platelets Function in Patients with Chronic Myeloid Leukaemia, V. Popov, A. Vladareanu, B. Matei, C. Matei, M. Omer, M. Andreescu, O. Patrinoiu, F. Mihai, M.G. Moisesescu, E. Kovacs, T. Savopol, H. Bumbea, 59th ASH Annual Meeting, 9-12 decembrie 2017, Atlanta, USA, This will be published online-only on the ASH abstracts site on December 8, 2017, and will become part of the permanent ASH and Blood abstracts archive; **impact factor 13.164 (2017)**.
90. STUDY OF TREATMENT IMPACT ON PATIENTS WITH ATLS, SIRS AND MOD ASSOCIATED WITH AGGRESSIVE HEMATOLOGICAL MALIGNANCIES - THE EXPERIENCE OF A ROMANIAN CENTER - Author(s): Mihaela Andreescu, Viola Popov, Daniela Georgescu, Felicia Mihai, Oana Patrinoiu, Mihaela Popescu, Mircea Munteanu, Adina Marina Urucu, Andreea Lacatusu, Ana-Maria Andreescu, Nicoleta Ilie, Alina Daniela Tanase EHA

Library. Andreescu M. 06/12/20; 297795; PB18.

91. CLL-033 Is Covid-19 infection a Trigger for Progression of CLL?- Authors: Viola Popov, Horia Bumbea, Mihaela Andreescu, Geanina Ofiteru, Felicia Mihai, Mihaela Popescu, Oana Patrinoiu, Daniela Georgescu, Claudia Despan, Meilin Omer; 2022/9/21; Clinical Lymphoma, Myeloma & Leukemia journal; vol. 22, pg. S140; **impact factor 2.822 (2022)**.
92. AML-168: the assessment of COVID-19 evolution in patients with oncological diseases admitted in an intensive care unit of one Romanian center. VM Popov, L Iliescu, C Pirvu, A Grigorie, O Constantin, A Rus, M. Andreescu. Clinical Lymphoma Myeloma and Leukemia 21, S285-S286; **impact factor 3.231 (2021)**.
93. AML-168: the assessment of COVID-19 evolution in patients with oncological diseases admitted in an intensive care unit of one Romanian center. VM Popov, L Iliescu, C Pirvu, A Grigorie, O Constantin, A Rus, D.M. Niculae Badoiu, A. Badea, M. Omer, M. Andreescu. Clinical Lymphoma Myeloma and Leukemia 21, S212; **impact factor 3.231 (2021)**.

CONFERINȚE ȘI SEMINARE

Am participat la peste 30 conferinte nationale si internationale (in calitate de speaker):

1. CML Treatment beyond the guidelines - country perspectives - 3rd CML Expert Summit - Lisbon 2014 - Mihaela Tevet.
2. JAK2 V617F, CALR AND C-MPL MUTATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS - BIOLOGICAL AND CLINICAL CORRELATES IN 199 PATIENTS - Adrian P. Trifa, Radu Popp, Andrei Cucuianu, Claudia Bănescu, Mihaela Tevet, Viola Popov, Bianca Martin, Camelia Andrei, Delia Dima, Anca Vasilache, Ljubomir Petrov, Laura Urian, Anca Bojan, Daniela Georgescu, Mihaela Popescu, Stefan Vesa, Mariela Militaru, Marcela Căndea, Gabriela Mocanu, Cristina Truică, Adriana Todincă, Alina Cătană, Romeo Mihăilă, Ioan V. Pop - CONGRESS OF THE ROMANIAN SOCIETY OF MEDICAL GENETICS, SEPTEMBER 24 - 26, 2014, HOTEL NOVOTEL, BUCHAREST.
3. „Hypereosinophilic syndromes FIP1L1/PDGFR fusion gene NEGATIVE-hematological remission on imatinib mesilate” - DG Georgescu, OP Patrinoiu, VP Popov, M Tevet, MB Balea, SZ Zurac, prezentat la Conferinta internationala a ISH Glasgow 2016, publicat in BRITISH JOURNAL OF HAEMATOLOGY 173, 175-176; **impact factor 4.501 (2016)**.
4. „The analyses of efficacy and tolerability of ruxolitinib in myelofibrosis patients-our experience - VM Popov, M Tevet, M Murat, CV Dragan, DG Georgescu, OFG Patrinoiu, prezentat la Conferinta internationala a ISH Glasgow 2016, publicat in BRITISH JOURNAL OF HAEMATOLOGY 173, 129-129; **impact factor 5.401 (2016)**.
5. TERT (TELOMERASE) RS2736100 A>C AND JAK2 RS10974944 C>G POLYMORPHISMS SIGNIFICANTLY INFLUENCE THE GENETIC PREDISPOSITION TO NONBCR-ABL MYELOPROLIFERATIVE NEOPLASMS - A MULTICENTRIC STUDY ON 500 PATIENTS Adrian Trifa, Andrei Cucuianu, Claudia Bănescu, Delia Dima, Mihaela Tevet, Anca Bojan, Anca Vasilache, Laura Urian, Tünde Török-Vistai, Ljubomir Petrov, Mihnea Zdrenghea, Meilin Murat, Viola Popov, Daniela Georgescu, Mihaela Popescu, Oana Patrinoiu, Marius Balea, Elena Coleş, Gabriela Mocanu, Carmen Şaguna, Gabriela Borsaru, Raluca Manolache, Irina Triantafyllidis, Mihaela Lebedenco, AnaMaria Ivănescu, Anca Ciobanu, Andrei Coliță, Nicoleta Berbec, Ana-Maria Vlădăreanu, Ana-Maria Neagu, Minodora Onisăi, Romeo Mihăilă, Horia Bumbea, Cristina Ciufu, Ioan V. Pop, Radu Popp, CONFERENCE OF THE ROMANIAN SOCIETY OF MEDICAL GENETICS OCTOBER 8 - 10, 2015 ARSENAL PARK, ORASTIE.
6. MOLECULAR MARKERS IN BCR/ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS. FROM DETECTION TO SELECTIVE THERAPY, Academician "N. Cajal" Simposion, Vth Edition, "Translational Oncology, Cell Therapy, Virology" Bucharest, 15-16 april 2010 . Autori: Carmen C.Diaconu , Mihaela Closca-Gheorghiu et all.
7. Exploring Molecular Mechanisms involved in Transformation of Hematopoietic Stem Cells in BCRABL Negative Myeloproliferative Neoplasms. Autori: Carmen C. Diaconu, Mihaela Closca (Tevet).
8. INTERNATIONAL TRAINING COURSE, 2nd ALUMNI CONFERENCE "Multidisciplinary Approaches to Biological Problems"; Chromosome 11 anomalies in acute leukemia - Arghir A, Bumbea H, Cisleanu D, Tevet M, Popov V, Neagu AM, Focsa IO, Papuc SM, Vladareanu AM, Tutulan-Cunita A - The 7 Conference of SRGM, Orastie, 8- 10.10.2015, review published in Rom J Rare Diseases, S1/2015:25 (ISSN 2068-5882).
9. The analyses of influence of platelet membrane fluidity in platelet receptors expression in chronic myeloproliferative neoplasms patients la 12th WORLD HEMATOLOGISTS CONGRESS, 15-16 martie 2018, Londra UK, autori: Viola M Popov, Ion Dumitru , Bogdan Matei, Christien O. Matei, Mihaela Andreescu, Meilin Omer, Felicia Mihai, Oana Patrinoiu, Mihaela G. Moiescu, Tudor Savopol, Ana Maria Vladareanu, Horia Bumbea, <https://www.omicsonline.org/conference-proceedings/2155-9864-C1-031-008.pdf>.
10. The assessment of JAK 2 mutation role in platelet membrane fluidity changes in chronic myeloproliferative neoplasms patients la XXXVII World Congress of the International Society of Hematology (ISH 2018), 13-16 septembrie 2018, Vancouver, Canada, autori: VM Popov, CO Matei, B Matei, A Trifa, F. Raicu, M. Omer, R. Leu, T. Savopol, MG Moiescu, E Kovacs, M Andreescu, AM Vladareanu, H. Bumbea.
11. Dragan Cornel, Tevet M, Georgescu D et al. The Role of Bone Marrow Transplantation in the Case of Treatment Associated AML - the Experience of One Hematology Department. Poster Presentation at ESH-EBMT 20Th Training Course on Haematopoietic Stem Cell Transplantation Budapest Hungary - May 11-14, 2016.
12. The 15th Congress of the European Hematology Association, Barcelona, June 2010, FAVORABLE RESPONSE TO ALPHA-INTERFERON IN A PEDIATRIC PATIENT WITH AGNOGENIC MYELOID METAPLASIA COMBINED WITH FV LEIDEN ANOMALY, Authors A Colita,1 A Colita,1 C Arion,1 ALupu,1 T Puscariu,2 C Dobrea,1 M Closca,3 O Ciocan,1 C Diaconu,4 M Chivu,4 R Talmaci,1 D Coriu,1 S Avram1, 1Carol Davila University of Medicine, Bucharest, Romania; 2Fundeni Institute, Bucharest, Romania; 3Coltea Hospital, Bucharest, Romania; 4Stefan Nicolau, Institute of Virology, Bucharest, Romania.
13. The 16th Congress of the European Hematology Association, London, June 2011, TREATMENT OF ELDERLY, UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH VALPROIC ACID AND LOW-DOSE MERCAPTOPYRINE, Authors A Colita,1 A Lupu,1 G Barca,2 N Berbec,1 M Closca,2 A Ciobanu,2 O Ciocan,1 C Saguna,1 S Angelescu,1 D Barbu,2 A Arghir,3 A Lungeanu,3 A Ivanescu,2 R Manolache2.

14. The 14th Congress of the European Hematology Association, Berlin, June 2009, FOLLICULAR LYMPHOMA: INCIDENCE, PROGNOSTIC FACTORS AND OVERALL SURVIVAL IN 78 PATIENTS FOLLOWED FOR 7 YEARS(2002-2008) FROM A SINGLE INSTITUTION, Authors C. Saguna, M. Closca, O. Ciocan, A. Colita, A. Ciobanu, N. Berbec, R. Manolache, E. Coles, A.R. Lupu, Coltea Hospital, Bucharest, Romania.
15. The 15th Congress of the European Hematology Association, Barcelona, June 2010, FAVORABLE RESPONSE TO ALPHA-INTERFERON IN A PEDIATRIC PATIENT WITH AGNOGENIC MYELOID METAPLASIA COMBINED WITH FV LEIDEN ANOMALY, Authors A Colita,1 A Colita,1 C Arion,1 ALupu,1 T Puscariu,2 C Dobrea,1 M Closca,3 O Ciocan,1 C Diaconu,4 M Chivu,4 R Talmaci,1 D Coriu,1 S Avram1, 1Carol Davila University of Medicine, Bucharest, Romania; 2Fundeni Institute, Bucharest, Romania; 3Coltea Hospital, Bucharest, Romania; 4Stefan Nicolau, Institute of Virology, Bucharest, Romania.
16. The 16th Congress of the European Hematology Association, London, June 2011, TREATMENT OF ELDERLY, UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH VALPROIC ACID AND LOW-DOSE MERCAPTOPYRINE, Authors A Colita,1 A Lupu,1 G Barca,2 N Berbec,1 M Closca,2 A Ciobanu,2 O Ciocan,1 C Saguna,1 S Angelescu,1 D Barbu,2 A Arghir,3 A Lungeanu,3 A Ivanescu,2 R Manolache2.
17. The 16th Congress of the European Hematology Association, London, June 2011, CHEMOTHERAPY WITH LOW-DOSE MERCAPTOPYRINE IN ELDERLY, UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) Authors A Colita,1 A Lupu,1 N Berbec,1 G Barca,2 O Ciocan,1 A Ciobanu,2 M Closca,2 C Saguna,1 S Angelescu,1 D Barbu,2 A Arghir,3, A Lungeanu,3 C Jardan4.
18. The 16th Congress of the European Hematology Association, London, June 2011, PROGNOSTIC FACTORS IN FOLLICULAR LYMPHOMA: A SINGLE INSTITUTION STUDY, Authors C Saguna, M Tevet, N Berbec, O Ciocan, A Colita, R Manolache, G Barca, C Dragan, S Nada, I Ciobanu, I Triantafyllidis, A Lupu, Coltea Hospital, Bucharest, Romania.
19. The 16th Congress of the European Hematology Association, London, June 2011, HODGKIN LYMPHOMA - PROGNOSIS AND EVOLUTION, Authors O Ciocan, A Ciobanu, I Triantafyllidis, C Draghici, A Colita, N Berbec, S Angelescu, M Tevet, G Barca, A Lupu, Coltea Hospital, Bucharest, Romania.
20. CLINICAL PROGNOSIS AND ADJUSTMENT OF THERAPEUTIC MANAGEMENT RELATED TO JAK2 V617F MUTATIONAL STATUS IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS, Academician "N. Cajal" Simposion, Vth Edition, "Translational Oncology, Cell Therapy, Virology" Bucharest, 15-16 april 2010. Autori: Mihaela Closca-Gheorghiu.
21. Mihaela Tevet, Daniela Georgescu et al. The role of Dexamethasone in the management of patients with Acute Myelogenous Leukemia. Oral Presentation at SRH Sinaia, 2016.
22. „The Treatment with 5 AZACITIDINE in MDS and AML – Practical aspects from the clinical experince of Colentina Clinical Hospital” - Dana Georgescu, Mihaela Tevet et al.. Oral Presentation Session Abstract – SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
23. „The experience of a single Center of Hematology in the treatment with hypomethylating agents” - Poster Abstract - Dana Georgescu, Mihaela Tevet et al. - SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
24. Apoptosis regulated protein levels and telomerase activity in high-grade non-Hodgkin's lymphomas, 32nd FEBS Congress - Molecular Machines, 7-12 iulie 2007, Viena, Austria, prezentare orala, publicat in culegerea de rezumate p.177 C.D.Goia, M. Cloșca, A.R.Lupu, A.Ciobanu, O.Ciocan, M.Anton, G.Anton,
25. „Variation and distribution of mast cells in benign and malignant lymphoid lesions” - M. D. Cioplea, S. Zurac, L. Sticlaru, S. Duțulescu, A. Stan, C. Popp, A. Oniga, G. Pop, M. Tevet, V. Chițu, F. Stăniceanu,. prezentare orala, publicat in 26th European Congress of Pathology. Virchows Archiv, 2014;465, Supplement 1:278.
26. „The Importance of CD36 Expression in Evaluation of Thrombotic Risk in Patients with Myeloproliferative Neoplasms”, lucrare publicata in Blood Online Blood 132(Suppl_1):4989-4989 * November 2018 si prezentata la ASH San Diego 2018, Viola Maria Popov, Meilin Omer, Adrian P Trifa, Ion Dumitru, Oana Patrinoiu, Mihaela Andreescu, Horia Bumbea; **impact factor 15.132 (2018).**
27. HemaSphere: June 2019 - Volume 3 - Issue S1 - p 984 si prezentata la EHA 24, Amsterdam 2019, „ASSESSMENT OF PLATELET MEMBRANE ALTERATION IN PATIENTS WITH MYELOID METAPLASIA WITH MYELOFIBROSIS” - Viola Maria Popov, Cristian Matei, Bogdan Matei, Rafaela Leu, Ion Dumitru, Cristina Dobrea, Adrian P Trifa, Anamaria Iova, Madalina Begu, Mihaela Georgeta Moisescu, Tudor Savopol, Eugenia Kovacs, Vladareanu AM, Meilin Omer, Mihaela Andreescu, Oana Patrinoiu, D.M. Georgescu, Horia Bumbea.

28. „The Importance of Fluorescence Anisotropy of Platelet Membrane in Platelet Receptor Expression in Chronic Patients with Chronic Myeloproliferative Neoplasms” la ESH International Conference on MPN, Saagart-Dublin, Irlanda, 15-17 mai 2018, autori: V Popov, H. Bumbea, T.Savopol, I. Dumitru, B.M.Matei, C.O Matei, M. Andreescu, M. Omer, F. Mihai, O Patrinoiu, A.M.Vladareanu, M.G. Moiescu.
29. „Global burden and treatment outcomes of invasive pulmonary aspergillosis in hematological patients” - case report. Sabina Schiopu, Mihaela Popescu, Mihaela Tevet, Oana Patrinoiu, Viola Popov, Daniela Georgescu et al. Oral Presentation Session Abstract - SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
30. „The management of acute leukemia - the experience of Colentina Hematology Department” - Oral Presentation Mihaela Popescu, Mihaela Tevet, Oana Patrinoiu, Viola Popov, Daniela Georgescu et al. Session Abstract - SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
31. The 13th Congress of the European Hematology Association, Copenhagen, June 2008, AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) ASSOCIATED TO NON-HODGKIN'S LYMPHOMA (NHL) Authors A. Colita,1 A.R. Lupu,1 S. Angelescu,1 D. Barbu2, G. Barca2, M. Closca2, C. Saguna,1 O. Ciocan,1 A. Ciobanu2, A.M. Ivanescu,1 M. Oprea2, D. Mut Popescu2, V. Teleanu2, A.Negulescu2, D. Coriu,3 A. Colita3 1Coltea Clinical Hospital/UMF Carol Davil, BUCHAREST; 2Coltea Hospital, BUCHAREST; 3Fundeni Institute/UMF carol Davila, BUCHAREST, Romania.
32. The 14th Congress of the European Hematology Association, Berlin, June 2009, HODGKIN LYMPHOMA – PROGNOSIS AND EVOLUTION, Authors O Ciocan, A Ciobanu, I Triantafyllidis, C Draghici, A Colita, N Berbec, S Angelescu, M Closca, G Barca, A Lupu, Coltea Hospital, Bucharest, Romania.
33. The 14th Congress of the European Hematology Association, Berlin, June 2009, NEW MOLECULAR MARKERS IN DIAGNOSIS OF SPLENIC LYMPHOMAS, Authors M. Closca- Gheorghiu, G. Ofiteru, A.R. Lupu, C. Saguna, O. Ciocan, A. Colita, A. Ciobanu, C. Mitrescu, E. Coles, Coltea Hospital, BUCHAREST, Romania.
34. Trombocitopenia, cheia în diagnosticul bolii Gaucher – Dr. Viola Maria Popov, Dr. Marius Balea, Dr.Mihaela Andreescu, Dr. Mihaela Popescu, Dr. Oana Patrinoiu, Dr. Meilin Omer, Dr. Felicia Mihai, Dr.Claudia Despan, Dr. Geanina Ofi teru, Dr. Camelia Dobrea,Dr. Rodica Gogulescu, Dr. Daniela Georgescu, prezentare orala Conferinta Colegiului Medicilor Bucuresti, Martie 2019.
35. JAK 2 V617F, CALR AND C-MPL MUTATION IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MIELOFIBROSIS- BIOLOGICAL AND CLINICAL CORRELATES IN 199 PATEIENTS, Adrian P. Trifa, Radu Popp, Andrei Cucuianu, Claudia Bănescu, Mihaela Tevet, Viola Popov et al.Congress of the Romanian Society of Medical Genetics Bucuresti 2014.
36. Analiza modificarilor fluiditatii si potentialului de membrana trombocitara la pacientii cu neoplazii mieloproliferative cronice,V. Popov, A. Vladareanu, B. Matei, C. Matei, M. Omer, M. Andreescu, O. Patrinoiu, F. Mihai, M.G. Moiescu, E. Kovacs, T. Savopol, H. Bumbea, A V-a Conferinta Nationala de Hemostaza si Tromboza (SRHT), 2-4 noiembrie 2017, Bucuresti, oral presentation.
37. Analiza modificarilor fluiditatii si potentialului de membrana trombocitara la pacientii cu neoplazii mieloproliferative cronice, V. Popov, A. Vladareanu, B. Matei, C. Matei, M. Omer, M. Andreescu, O. Patrinoiu, F. Mihai, M.G. Moiescu, E. Kovacs, T. Savopol, H. Bumbea, A V-a Conferinta Nationala de Hemostaza si Tromboza (SRHT), 2-4 noiembrie 2017, Bucuresti, Romania , oral presentation.
38. ASSESSMENT OF PLATELET MEMBRANE ALTERATION IN PATIENTS WITH MYELOID METAPLASIA WITH MYELOFIBROSIS Viola Popov, Cristien Oktaviani Matei, Bogdan Mircea Matei, Rebeca Leu, Ion Dumitru, Camelia Dobrea, Adrian Trifa, AnaMaria Iova, Madalina Begu, Mihaela Georgeta Moiescu, Tudor Savopol, Eugenia Kovacs, Ana Maria Vladareanu, Meilin Omer, Mihaela Andreescu, Oana Patrinoiu, Daniela Georgescu, Horia Bumbea EHA Library. Popov V. 05/16/19; 268109; PB2195.
39. The analyses of influence of platelet membrane fluidity in platelet receptors expression in chronic myeloproliferative neoplasms patients Viola M Popov, Ion Dumitru , Bogdan Matei, Christien O. Matei, Mihaela Andreescu, Meilin Omer, Felicia Mihai, Oana Patrinoiu, Mihaela G. Moiescu, Tudor Savopol, Ana Maria Vladareanu, Horia Bumbea, Prezentare orala: la 12th WORLD HEMATOLOGISTS CONGRESS, 15-16 martie 2018, Londra UK, , <https://www.omicsonline.org/conference-proceedings/2155-9864-C1-031-008.pdf>;
40. The analyses of thrombotic risk in chronic myeloproliferative neoplasms patients, V.M. Popov, A. Trifa, M. Omer, M. Andreescu, F. Mihai, F. Raicu, S. Chioveanu, A. M. Grigoriu, Poster 10th International Congress on Myeloproliferative Neoplasms and Chronic Myeloid Leukemia, 2-3 noiembrie 2017, New York 2017 P104.

41. THROMBOTIC COMPLICATIONS IN HEMATOLOGIC MALIGNANCIES Author(s): Mihaela Popescu, Daniela Georgescu, Marius Balea, Mihaela Tevet, Oana Patrinoiu, Meilin Murat, Felicia Mihai, Cornel Dragan, Viola Popov, Anda-Natalia Ciuhu EHA Library. Popescu M. 06/09/16; 135104; PB2204.
42. STUDY OF TREATMENT IMPACT ON PATIENTS WITH ATLS, SIRS AND MOD ASSOCIATED WITH AGGRESSIVE HEMATOLOGICAL MALIGNANCIES - THE EXPERIENCE OF A ROMANIAN CENTER Author(s): Mihaela Andreescu, Viola Popov, Daniela Georgescu, Felicia Mihai, Oana Patrinoiu, Mihaela Popescu, Mircea Munteanu, Adina Marina Urucu, Andreea Lacatusu, Ana-Maria Andreescu, Nicoleta Ilie, Alina Daniela Tanase EHA Library. Andreescu M. 06/12/20; 297795; PB187.
43. The assessment of JAK 2 mutation role in platelet membrane fluidity changes in chronic myeloproliferative neoplasms patients la XXXVII World Congress of the International Society of Hematology (ISH 2018), 13-16 septembrie 2018, Vancouver, Canada, autori: VM Popov, CO Matei, B Matei, A. Trifa, F. Raicu, M. Omer, R. Leu, T. Savopol, MG Moisescu, E Kovacs, M Andreescu, AM Vladareanu, H. Bumbea.
44. Dragan Cornel, Tevet M, Georgescu D et al. The Role of Bone Marrow Transplantation in the Case of Treatment Associated AML - the Experience of One Hematology Department. Poster Presentation at ESH-EBMT 20Th Training Course on Haematopoietic Stem Cell Transplantation Budapest Hungary - May 11-14, 2016.
45. The 15th Congress of the European Hematology Association, Barcelona, June 2010, FAVORABLE RESPONSE TO ALPHA-INTERFERON IN A PEDIATRIC PATIENT WITH AGNOGENIC MYELOID METAPLASIA COMBINED WITH FV LEIDEN ANOMALY, Authors A Colita,1 A Colita,1 C Arion,1 ALupu,1 T Puscariu,2 C Dobrea,1 M Closca,3 O Ciocan,1 C Diaconu,4 M Chivu,4 R Talmaci,1 D Coriu,1 S Avram1, 1Carol Davila University of Medicine, Bucharest, Romania; 2Fundeni Institute, Bucharest, Romania; 3Coltea Hospital, Bucharest, Romania; 4Stefan Nicolau, Institute of Virology, Bucharest, Romania.
46. The 16th Congress of the European Hematology Association, London, June 2011, TREATMENT OF ELDERLY, UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH VALPROIC ACID AND LOW-DOSE MERCAPTOPYRINE, Authors A Colita,1 A Lupu,1 G Barca,2 N Berbec,1 M Closca,2 A Ciobanu,2 O Ciocan,1 C Saguna,1 S Angelescu,1 D Barbu,2 A Arghir,3 A Lungeanu,3 A Ivanescu,2 R Manolache2.
47. The 14th Congress of the European Hematology Association, Berlin, June 2009, FOLLICULAR LYMPHOMA: INCIDENCE, PROGNOSTIC FACTORS AND OVERALL SURVIVAL IN 78 PATIENTS FOLLOWED FOR 7 YEARS(2002-2008) FROM A SINGLE INSTITUTION, Authors C. Saguna, M. Closca, O. Ciocan, A. Colita, A. Ciobanu, N. Berbec, R. Manolache, E. Coles, A.R. Lupu, Coltea Hospital, Bucharest, Romania.
48. The 15th Congress of the European Hematology Association, Barcelona, June 2010, FAVORABLE RESPONSE TO ALPHA-INTERFERON IN A PEDIATRIC PATIENT WITH AGNOGENIC MYELOID METAPLASIA COMBINED WITH FV LEIDEN ANOMALY, Authors A Colita,1 A Colita,1 C Arion,1 ALupu,1 T Puscariu,2 C Dobrea,1 M Closca,3 O Ciocan,1 C Diaconu,4 M Chivu,4 R Talmaci,1 D Coriu,1 S Avram1, 1Carol Davila University of Medicine, Bucharest, Romania; 2Fundeni Institute, Bucharest, Romania; 3Coltea Hospital, Bucharest, Romania; 4Stefan Nicolau, Institute of Virology, Bucharest, Romania.
49. The 16th Congress of the European Hematology Association, London, June 2011, TREATMENT OF ELDERLY, UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH VALPROIC ACID AND LOW-DOSE MERCAPTOPYRINE, Authors A Colita,1 A Lupu,1 G Barca,2 N Berbec,1 M Closca,2 A Ciobanu,2 O Ciocan,1 C Saguna,1 S Angelescu,1 D Barbu,2 A Arghir,3 A Lungeanu,3 A Ivanescu,2 R Manolache2.
50. The 16th Congress of the European Hematology Association, London, June 2011, CHEMOTHERAPY WITH LOW-DOSE MERCAPTOPYRINE IN ELDERLY, UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) Authors A Colita,1 A Lupu,1 N Berbec,1 G Barca,2 O Ciocan,1 A Ciobanu,2 M Closca,2 C Saguna,1 S Angelescu,1 D Barbu,2 A Arghir,3, A Lungeanu,3 C Jordan4.
51. The 16th Congress of the European Hematology Association, London, June 2011, PROGNOSTIC FACTORS IN FOLLICULAR LYMPHOMA: A SINGLE INSTITUTION STUDY, Authors C Saguna, M Tevet, N Berbec, O Ciocan, A Colita, R Manolache, G Barca, C Dragan, S Nada, I Ciobanu, I Triantafyllidis, A Lupu, Coltea Hospital, Bucharest, Romania.
52. The 16th Congress of the European Hematology Association, London, June 2011, HODGKIN LYMPHOMA - PROGNOSIS AND EVOLUTION, Authors O Ciocan, A Ciobanu, I Triantafyllidis, C Draghici, A Colita, N Berbec, S Angelescu, M Tevet, G Barca, A Lupu, Coltea Hospital, Bucharest, Romania.
53. CLINICAL PROGNOSIS AND ADJUSTMENT OF THERAPEUTIC MANAGEMENT RELATED TO JAK2 V617F MUTATIONAL STATUS IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS, Academician "N. Cajal" Simposion, Vth Edition, "Translational Oncology, Cell Therapy, Virology" Bucharest, 15-16 april 2010. Autori: Mihaela Closca-Gheorghiu.
54. Mihaela Tevet, Daniela Georgescu et al. The role of Dexamethasone in the management of patients with Acute Myelogenous Leukemia. Oral Presentation at SRH Sinaia, 2016.

55. „The Treatment with 5 AZACITIDINE in MDS and AML – Practical aspects from the clinical experince of Colentina Clinical Hospital” - Dana Georgescu, Mihaela Tevet et al.. Oral Presentation Session Abstract – SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
56. „The experience of a single Center of Hematology in the treatment with hypomethylating agents” - Poster Abstract - Dana Georgescu, Mihaela Tevet et al. - SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
57. Apoptosis regulated protein levels and telomerase activity in high-grade non-Hodgkin's lymphomas, 32nd FEBS Congress - Molecular Machines, 7-12 iulie 2007, Viena, Austria, prezentare orala, publicat in culegerea de rezumate p.177 C.D.Goia, M. Cloșca, A.R.Lupu, A.Ciobanu, O.Ciocan, M.Anton, G.Anton,
58. „Variation and distribution of mast cells in benign and malignant lymphoid lesions” - M. D. Cioplea, S. Zurac, L. Sticlaru, S. Duțulescu, A. Stan, C. Popp, A. Oniga, G. Pop, M. Tevet, V. Chițu, F. Stăniceanu,. prezentare orala, publicat in 26th European Congress of Pathology. Virchows Archiv, 2014;465, Supplement 1:278.
59. „The Importance of CD36 Expression in Evaluation of Thrombotic Risk in Patients with Myeloproliferative Neoplasms”, lucrare publicata in Blood Online Blood 132(Suppl_1):4989-4989 * November 2018 si prezentata la ASH San Diego 2018, Viola Maria Popov, Meilin Omer, Adrian P Trifa, Ion Dumitru, Oana Patrinoiu, Mihaela Andreescu, Horia Bumbea; **impact factor 15.132 (2018)**.
60. HemaSphere: June 2019 - Volume 3 - Issue S1 - p 984 si prezentata la EHA 24, Amsterdam 2019, „ASSESSMENT OF PLATELET MEMBRANE ALTERATION IN PATIENTS WITH MYELOID METAPLASIA WITH MYELOFIBROSIS” - Viola Maria Popov, Cristian Matei, Bogdan Matei, Rafaela Leu, Ion Dumitru, Cristina Dobreă, Adrian P Trifa, Anamaria Iova, Madalina Begu, Mihaela Georgeta Moisescu, Tudor Savopol, Eugenia Kovacs, Vladareanu AM, Meilin Omer, Mihaela Andreescu, Oana Patrinoiu, D.M. Georgescu, Horia Bumbea.
61. „The Importance of Fluorescence Anisotropy of Platelet Membrane in Platelet Receptor Expression in Chronic Patients with Chronic Myeloproliferative Neoplasms” la ESH International Conference on MPN, Saagart-Dublin, Irlanda, 15-17 mai 2018, autori: V Popov, H. Bumbea, T.Savopol, I. Dumitru, B.M.Matei, C.O Matei, M. Andreescu, M. Omer, F. Mihai, O Patrinoiu, A.M.Vladareanu, M.G. Moisescu.
62. „Global burden and treatment outcomes of invasive pulmonary aspergillosis in hematological patients” - case report. Sabina Schiopu, Mihaela Popescu, Mihaela Tevet, Oana Patrinoiu, Viola Popov, Daniela Georgescu et al. Oral Presentation Session Abstract - SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
63. „The management of acute leukemia - the experience of Colentina Hematology Department” - Oral Presentation Mihaela Popescu, Mihaela Tevet, Oana Patrinoiu, Viola Popov, Daniela Georgescu et al. Session Abstract - SRH 2015. DOCUMENTA HAEMATOLOGICA Supplement -2015.
64. The 13th Congress of the European Hematology Association, Copenhagen, June 2008, AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) ASSOCIATED TO NON-HODGKIN'S LYMPHOMA (NHL) Authors A. Colita,1 A.R. Lupu,1 S. Angelescu,1 D. Barbu2, G. Barca2, M. Closca2, C. Saguna,1 O. Ciocan,1 A. Ciobanu2, A.M. Ivanescu,1 M. Oprea2, D. Mut Popescu2, V. Teleanu2, A.Negulescu2, D. Coriu,3 A. Colita3 1Coltea Clinical Hospital/UMF Carol Davila, BUCHAREST; 2Coltea Hospital, BUCHAREST; 3Fundeni Institute/UMF carol Davila, BUCHAREST, Romania.
65. The 14th Congress of the European Hematology Association, Berlin, June 2009, HODGKIN LYMPHOMA – PROGNOSIS AND EVOLUTION, Authors O Ciocan, A Ciobanu, I Triantafyllidis, C Draghici, A Colita, N Berbec, S Angelescu, M Closca, G Barca, A Lupu, Coltea Hospital, Bucharest, Romania.
66. The 14th Congress of the European Hematology Association, Berlin, June 2009, NEW MOLECULAR MARKERS IN DIAGNOSIS OF SPLENIC LYMPHOMAS, Authors M. Closca- Gheorghiu, G. Ofiteru, A.R. Lupu, C. Saguna, O. Ciocan, A. Colita, A. Ciobanu, C. Mitrescu, E. Coles, Coltea Hospital, BUCHAREST, Romania.
67. Trombocitopenia, cheia în diagnosticul bolii Gaucher – Dr. Viola Maria Popov, Dr. Marius Balea, Dr.Mihaela Andreescu, Dr. Mihaela Popescu, Dr. Oana Patrinoiu, Dr. Meilin Omer, Dr. Felicia Mihai, Dr.Claudia Despan, Dr. Geanina Ofi teru, Dr. Camelia Dobreă,Dr. Rodica Gogulescu, Dr. Daniela Georgescu, prezentare orala Conferinta Colegiului Medicilor Bucuresti, Martie 2019.
68. JAK 2 V617F, CALR AND C-MPL MUTATION IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MIELOFIBROSIS- BIOLOGICAL AND CLINICAL CORRELATES IN 199 PATEIENTS, Adrian P. Trifa, Radu Popp, Andrei Cucuianu, Claudia Bănescu, Mihaela Tevet, Viola Popov et al.Congress of the Romanian Society of Medical Genetics Bucuresti 2014.
69. Analiza modificarilor fluiditatii si potentialului de membrana trombocitara la pacientii cu neoplazii mieloproliferative cronice,V. Popov, A. Vladareanu, B. Matei, C. Matei, M. Omer, M. Andreescu, O. Patrinoiu, F. Mihai, M.G. Moisescu, E. Kovacs, T. Savopol, H. Bumbea, A V-a Conferinta Nationala de Hemostaza si Tromboza (SRHT), 2-4 noiembrie 2017, Bucuresti, oral presentation.

70. Analiza modificarilor fluiditatii si potentialului de membrana trombocitara la pacientii cu neoplazii mieloproliferative cronice, V. Popov, A. Vladareanu, B. Matei, C. Matei, M. Omer, M. Andreescu, O. Patrinoiu, F. Mihai, M.G. Moiescu, E. Kovacs, T. Savopol, H. Bumbea, A V-a Conferinta Nationala de Hemostaza si Tromboza (SRHT), 2-4 noiembrie 2017, Bucuresti, Romania , oral presentation.
71. ASSESSMENT OF PLATELET MEMBRANE ALTERATION IN PATIENTS WITH MYELOID METAPLASIA WITH MYELOFIBROSIS Viola Popov, Cristien Oktaviani Matei, Bogdan Mircea Matei, Rebeca Leu, Ion Dumitru, Camelia Dobrea, Adrian Trifa, AnaMaria Iova, Madalina Begu, Mihaela Georgeta Moiescu, Tudor Savopol, Eugenia Kovacs, Ana Maria Vladareanu, Meilin Omer, Mihaela Andreescu, Oana Patrinoiu, Daniela Georgescu, Horia Bumbea EHA Library. Popov V. 05/16/19; 268109; PB2195.
72. The analyses of influence of platelet membrane fluidity in platelet receptors expression in chronic myeloproliferative neoplasms patients Viola M Popov, Ion Dumitru , Bogdan Matei, Christien O. Matei, Mihaela Andreescu, Meilin Omer, Felicia Mihai, Oana Patrinoiu, Mihaela G. Moiescu, Tudor Savopol, Ana Maria Vladareanu, Horia Bumbea, Prezentare orala: la 12th WORLD HEMATOLOGISTS CONGRESS, 15-16 martie 2018, Londra UK, , <https://www.omicsonline.org/conference-proceedings/2155-9864-C1-031-008.pdf>;
73. The analyses of thrombotic risk in chronic myeloproliferative neoplasms patients, V.M. Popov, A. Trifa, M. Omer, M. Andreescu, F. Mihai, F. Raicu, S. Chioveanu, A. M. Grigoriu, Poster 10th International Congress on Myeloproliferative Neoplasms and Chronic Myeloid Leukemia, 2-3 noiembrie 2017, New York 2017 P104.
74. THROMBOTIC COMPLICATIONS IN HEMATOLOGIC MALIGNANCIES Author(s): Mihaela Popescu, Daniela Georgescu, Marius Balea, Mihaela Tevet, Oana Patrinoiu, Meilin Murat, Felicia Mihai, Cornel Dragan, Viola Popov, Anda-Natalia Ciuhu EHA Library. Popescu M. 06/09/16; 135104; PB2204.
75. STUDY OF TREATMENT IMPACT ON PATIENTS WITH ATLS, SIRS AND MOD ASSOCIATED WITH AGGRESSIVE HEMATOLOGICAL MALIGNANCIES - THE EXPERIENCE OF A ROMANIAN CENTER Author(s): Mihaela Andreescu, Viola Popov, Daniela Georgescu, Felicia Mihai, Oana Patrinoiu, Mihaela Popescu, Mircea Munteanu, Adina Marina Urucu, Andreea Lacatusu, Ana-Maria Andreescu, Nicoleta Ilie, Alina Daniela Tanase EHA Library. Andreescu M. 06/12/20; 297795; PB.
76. Genomic abnormalities in acute myeloid leukemia with normal karyotype- Authors: Aurora Arghir, Sorina Mihaela Papuc, Andreea-Cristina Tutulan-Cunita, Raluca Colesniuc, Ioana Borcan, Silvana Angelescu, Mihaela Andreescu, Diana Cisleanu, Ana-Maria Vladareanu, Horia Bumbea; 2017/6/29; Molecular Cytogenetics conference; vol. 10, editor Biomed Central LTD.
77. Clinical significance of JAK2 mutation in patients with chronic MPN and evaluation of it as a risk factor for hemorrhagic complication in these disorders- Authors: M Tevet, A Lupu, C Saguna, C Dragan, A Colita, G Barca; 2012/7/16; Haematologica conference; vol. 97, pg. 636-636, editor Ferrata Storti Foundation; **impact factor 5.935 (2012)**.
78. The role of JAK2-V617F mutation in leukemic transformation of myeloproliferative neoplasms- Authors: M Tevet, A Lupu, C Saguna, C Dragan, A Colita, G Barca; 2012/7/16; Haematologica conference; vol. 97, pg. 633-633, editor Ferrata Storti Foundation; **impact factor 5.935 (2012)**.
79. Myelodysplastic syndromes: challenging disorders for cytogeneticists and hematologists- Authors: Aurora Arghir, Sorina Mihaela Chirieac, Ana Maria Vladareanu, Mihaela Closca, Horia Bumbea, Gabriela Mocanu, Nicoleta Berbec, Ioana Borcan, Andreea Tutulan-Cunita; 2011/6/1; Chromosome Research conference; vol. 19, pg. S159-S160; editor Springer; **impact factor 3.087 (2011)**.

STUDII CLINICE

Investigator principal si subinvestigator intr-o serie de studii clinice:

1. B3281006 A Phase 3, Randomized, Double-Blind Study Of Pf-05280586 Versus Rituximab For The First-Line Treatment Of Patients With Cd20-Positive, Low Tumor Burden, Follicular Lymphoma ongoing 6 patients screened 1 randomised closed 2018
2. 54767414MMY3007, A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy ongoing 7 patients screened, 6 patients randomized ongoing
3. C25006 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma ongoing
4. CT-P10 3.4 LTBFL A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma 1 patient screened. Closed 2018
5. AC220-A-U302 (QuANTUM-First) study A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia 38 patients screened, 2 randomised, ongoing
6. HEL16652_PRAN-16-52 A Phase III, Global, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients ≥ 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy, 16 patients screened, 6 randomised closed
7. KCP-330-023 A PHASE 3 RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE (SVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM), 3 patients screened 3 randomised, ongoing
8. CHRONOS-3 A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ongoing, 2 patients screened, 1 patient randomized
9. CHRONOS-4 A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed iNHL ongoing, 4 patients screened, 2 patients randomized
10. AMG 981 20150262- 20150262 Real-World Evidence of the Use of Carfilzomib among Patients with Relapsed or Refractory Multiple Myeloma in Europe, observational study, 5 patients enrolled, closed
11. HES200622, A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622, 3 patients screened, 2 randomised, ongoing
12. UCB-TP0004, Un Studiu-Extensie În Regim Deschis, De Investigare A Siguranței, Tolerabilității Și Eficacității Pe Termen Lung Ale Rozanolixizumabului La Participanții La Studiu Cu Trombocitopenie Imună Primară (Tip Persistentă Sau Cronică, NOT STARTED
13. SPARC - CLR_15_03, A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
14. SB12-3003 A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB12 (proposed eculizumab biosimilar) and Soliris® in Subjects with Paroxysmal Nocturnal Haemoglobinuria, 1 patient screened and randomized, ongoing.
15. CA0731020 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma 7 patients screened, 2 randomised, ongoing
16. CA057008 Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib

and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2, 3 patients screened, 1 randomised, ongoing

17. TAK-771-5006 A Prospective, Observational Study to Assess the Real World Usage and Outcomes of HyQvia in Patients with Multiple Myeloma (MM) diagnosed with secondary Immunodeficiency (SID) 3 screened, 3 randomised, ongoing

Articole in care s-a realizat peer review:

1. In patients with JAK2 Unmutated CMN, Are CalR and MPL Gene Mutations Predictive of Diagnosis or Clinical Course, *Medicina* (April 13 and May 9, 2025);
2. Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study, *Journal of Personalized Medicine* (March 25, 2025);
3. Construction and Validation of Nomogram Prediction Model for Recurrent Spontaneous Abortion Based on the Expression of MALAT1, miR-515-5p, and MCL1 mRNA, *International Journal of Women's Health* (March 7, 2025);
4. Evaluation of Three Large Language Model's Responses to Inquiries Regarding Post-abortion Care in the Context of Chinese Language: A Comparative Analysis, Risk Management and Healthcare Policy (May 11, 2025);
5. External validation of JAKPOT score for diagnosing JAK2-positive erythrocytosis: A retrospective cohort study, *Journal of Clinical Medicine* (May 10, 2025);
6. In Patients with JAK2 Unmutated CMN, Are CalR and MPL Gene Mutations Predictive of Diagnosis or Clinical Course?, *Medicina* (April 13 and May 9, 2025);
7. Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study, *Journal of Personalized Medicine* (March 25, 2025);
8. Certificate of Excellence in Reviewing in recognition of an outstanding contribution to the quality of the journal (*Journal of Cancer and Tumor International*, March 20 2025)- Certificate no. PRJCT133028MIH;
9. Reviewed 1 submission in the Journal: *International Journal of Women's Health* during 2025 (Dovepress).

● **MEMBRA IN SOCIETATILE NATIONALE SI INTERNATIONALE DE HEMATOLOGIE**

- Membra a Societatii Americane de Hematologie,
- Membra a Societatii Europene de Hematologie,
- Membra fondatoare si Secretara a Societatii Romane de Transplant Medular,
- Membra a Societatii Romane de Hematologie,
- Membra a Societatii Romane de Hemostaza si Tromboza,
- Membra a Myeloma Euronet
- Membra a European Myeloma Network